nct_id,start_date,study_type,brief_title,overall_status,phase,sponsor,ctg_links,Abstract,Registry,Total_pubs,vaccine_trial_flag,Number_of_updates,US_site_flag,Has_Results,country,mapped_intervention
NCT04326790,4/3/2020,Interventional,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,Recruiting,Phase 2,National and Kapodistrian University of Athens,https://clinicaltrials.gov/ct2/show/NCT04326790,2,0,2,0,4,0,0,Gibraltar,colchicine|standard care
NCT04292964,3/1/2020,Observational,Prognostic Factors of Patients With COVID-19,Completed,NA,Chongqing Medical University,https://clinicaltrials.gov/ct2/show/NCT04292964,2,0,2,0,3,0,0,China,"NA"
NCT04315948,3/22/2020,Interventional,Trial of Treatments for COVID-19 in Hospitalized Adults,Recruiting,Phase 3,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",https://clinicaltrials.gov/ct2/show/NCT04315948,3,0,3,0,6,0,0,Belgium|Austria|France|Luxembourg|Portugal,remdesivir|lopinavir/ritonavir|interferon|hydroxychloroquine|standard care|lopinavir|ritonavir
NCT04323527,3/23/2020,Interventional,Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2,Completed,Phase 2,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,https://clinicaltrials.gov/ct2/show/NCT04323527,1,0,1,0,3,0,0,Brazil,chloroquine
NCT04279782,1/20/2020,Observational,Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection,Recruiting,NA,"Third Affiliated Hospital, Sun Yat-Sen University",https://clinicaltrials.gov/ct2/show/NCT04279782,1,0,1,0,1,0,0,China,comprehensive treatment
NCT04318366,3/19/2020,Observational,"COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor",Recruiting,NA,UniversitÃ  Vita-Salute San Raffaele,https://clinicaltrials.gov/ct2/show/NCT04318366,7,0,7,0,3,0,0,Italy,observational
NCT04355936,5/19/2020,Interventional,Telmisartan for Treatment of COVID-19 Patients,Completed,Phase 4,Laboratorio Elea Phoenix S.A.,https://clinicaltrials.gov/ct2/show/NCT04355936,1,0,1,0,8,0,0,Argentina,telmisartan|standard care
NCT04308668,3/17/2020,Interventional,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Completed,Phase 3,University of Minnesota,https://clinicaltrials.gov/ct2/show/NCT04308668,3,1,4,0,9,1,0,United States|Canada,hydroxychloroquine|placebo
NCT04321278,3/28/2020,Interventional,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),Completed,Phase 3,Hospital Israelita Albert Einstein,https://clinicaltrials.gov/ct2/show/NCT04321278,2,0,2,0,6,0,0,Brazil,hydroxychloroquine / azithromycin|hydroxychloroquine|azithromycin
NCT04261517,2/6/2020,Interventional,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,Completed,Phase 3,Shanghai Public Health Clinical Center,https://clinicaltrials.gov/ct2/show/NCT04261517,1,0,1,0,3,0,0,China,hydroxychloroquine
NCT04276688,2/10/2020,Interventional,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment",Completed,Phase 2,The University of Hong Kong,https://clinicaltrials.gov/ct2/show/NCT04276688,3,0,3,0,2,0,0,Hong Kong,lopinavir/ritonavir|ribavirin|interferon|lopinavir|ritonavir
NCT04345848,4/28/2020,Interventional,Preventing COVID-19 Complications With Low- and High-dose Anticoagulation,Recruiting,Phase 3,"University Hospital, Geneva",https://clinicaltrials.gov/ct2/show/NCT04345848,4,0,4,0,3,0,0,Switzerland,enoxaparin
NCT04372589,5/20/2020,Interventional,Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC),Recruiting,Phase 2/Phase 3,University of Manitoba,https://clinicaltrials.gov/ct2/show/NCT04372589,5,0,5,1,3,1,0,United States|Brazil|Canada|Mexico,heparin
NCT04367831,5/2/2020,Interventional,Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19,Recruiting,Phase 4,Columbia University,https://clinicaltrials.gov/ct2/show/NCT04367831,4,0,4,0,2,1,0,United States,enoxaparin|heparin|enoxaparin/lovenox|lovenox
NCT04366960,5/14/2020,Interventional,Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients,Recruiting,Phase 3,Niguarda Hospital,https://clinicaltrials.gov/ct2/show/NCT04366960,4,0,4,0,3,0,0,Italy,enoxaparin
NCT04257656,2/6/2020,Interventional,A Trial of Remdesivir in Adults With Severe COVID-19,Terminated,Phase 3,Capital Medical University,https://clinicaltrials.gov/ct2/show/NCT04257656,2,0,2,0,3,0,0,China,remdesivir|placebo
NCT04329832,3/30/2020,Interventional,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,"Active, not recruiting",Phase 2,"Intermountain Health Care, Inc.",https://clinicaltrials.gov/ct2/show/NCT04329832,2,0,2,0,3,1,0,United States,hydroxychloroquine|azithromycin
NCT04374071,3/12/2020,Observational,Early Short Course Corticosteroids in COVID-19,Completed,NA,Henry Ford Health System,https://clinicaltrials.gov/ct2/show/NCT04374071,1,0,1,0,0,1,0,United States,methylprednisolone
NCT04280705,2/21/2020,Interventional,Adaptive COVID-19 Treatment Trial (ACTT),Completed,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),https://clinicaltrials.gov/ct2/show/NCT04280705,8,0,8,0,24,1,1,"United States|Denmark|Germany|Greece|Japan|Korea, Republic of|Mexico|Singapore|Spain|United Kingdom",placebo|remdesivir
NCT04313127,3/16/2020,Interventional,Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults,"Active, not recruiting",Phase 1,CanSino Biologics Inc.,https://clinicaltrials.gov/ct2/show/NCT04313127,1,0,1,1,4,0,0,China,adenovirus type 5 vector
NCT04292899,3/6/2020,Interventional,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe Coronavirus Disease (COVID-19),Completed,Phase 3,Gilead Sciences,https://clinicaltrials.gov/ct2/show/NCT04292899,1,0,1,0,20,1,1,"United States|China|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Netherlands|Singapore|Spain|Sweden|Switzerland|Taiwan|United Kingdom",remdesivir|standard care
NCT04321421,3/17/2020,Interventional,Hyperimmune Plasma for Critical Patients With COVID-19,Completed,N/A,Foundation IRCCS San Matteo Hospital,https://clinicaltrials.gov/ct2/show/NCT04321421,16,0,16,0,2,0,0,Italy,convalescent plasma
NCT04324736,3/10/2020,Observational,"""COVID-19 and Diabetes Outcomes""","Active, not recruiting",NA,Nantes University Hospital,https://clinicaltrials.gov/ct2/show/NCT04324736,2,0,2,0,6,0,0,France,no interventional study
NCT04354701,3/17/2020,Observational [Patient Registry],COVID-19 and Cancer Consortium Registry,Recruiting,NA,Vanderbilt-Ingram Cancer Center,https://clinicaltrials.gov/ct2/show/NCT04354701,1,0,1,0,4,1,0,United States,web-based redcap survey
NCT04332991,4/2/2020,Interventional,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Completed,Phase 3,Massachusetts General Hospital,https://clinicaltrials.gov/ct2/show/NCT04332991,2,0,2,0,6,1,0,United States,hydroxychloroquine|placebo
NCT04330638,4/3/2020,Interventional,Treatment of COVID-19 Patients With Anti-interleukin Drugs,"Active, not recruiting",Phase 3,"University Hospital, Ghent",https://clinicaltrials.gov/ct2/show/NCT04330638,1,0,1,0,6,0,0,Belgium,standard care|anakinra|siltuximab|tocilizumab
NCT04343768,4/9/2020,Interventional,"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial",Completed,Phase 2,Shahid Beheshti University of Medical Sciences,https://clinicaltrials.gov/ct2/show/NCT04343768,1,0,1,0,3,0,0,"Iran, Islamic Republic of",hydroxychloroquine|lopinavir/ritonavir|interferon|lopinavir|ritonavir
NCT04328961,3/31/2020,Interventional,Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP),Completed,Phase 2/Phase 3,University of Washington,https://clinicaltrials.gov/ct2/show/NCT04328961,2,0,2,0,5,1,0,United States,hydroxychloroquine|vitamin c
NCT04331171,3/17/2020,Observational [Patient Registry],Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients' Triage,Recruiting,NA,Weprom,https://clinicaltrials.gov/ct2/show/NCT04331171,2,0,2,0,3,0,0,France,web application users
NCT04328441,3/25/2020,Interventional,Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine,"Active, not recruiting",Phase 3,UMC Utrecht,https://clinicaltrials.gov/ct2/show/NCT04328441,1,0,1,1,3,0,0,Netherlands,bcg|placebo
NCT04360980,3/20/2020,Interventional,The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection,Recruiting,Phase 2,Shahid Beheshti University of Medical Sciences,https://clinicaltrials.gov/ct2/show/NCT04360980,1,0,1,0,3,0,0,"Iran, Islamic Republic of",colchicine
NCT04333589,4/1/2020,Interventional,Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive,Recruiting,N/A,Peking University First Hospital,https://clinicaltrials.gov/ct2/show/NCT04333589,1,0,1,0,2,0,0,China,favipiravir
NCT04316377,3/25/2020,Interventional,Norwegian Coronavirus Disease 2019 Study,"Active, not recruiting",Phase 4,"University Hospital, Akershus",https://clinicaltrials.gov/ct2/show/NCT04316377,2,0,2,0,3,0,0,Norway,hydroxychloroquine
NCT04326920,3/24/2020,Interventional,Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC),"Active, not recruiting",Phase 4,"University Hospital, Ghent",https://clinicaltrials.gov/ct2/show/NCT04326920,2,0,2,0,4,0,0,Belgium,sargramostim|control
NCT04306393,3/21/2020,Interventional,Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19,Recruiting,Phase 2,Massachusetts General Hospital,https://clinicaltrials.gov/ct2/show/NCT04306393,1,0,1,0,7,1,0,United States,nitric oxide
NCT04335786,4/17/2020,Interventional,Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease,Recruiting,Phase 4,Radboud University,https://clinicaltrials.gov/ct2/show/NCT04335786,1,0,1,0,6,0,0,Netherlands,diovan|placebo
NCT04341493,4/6/2020,Interventional,Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19,Recruiting,Phase 4,Materno-Perinatal Hospital of the State of Mexico,https://clinicaltrials.gov/ct2/show/NCT04341493,1,0,1,0,2,0,0,Mexico,nitazoxanide|hydroxychloroquine
NCT04334265,4/1/2020,Interventional,Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019,Recruiting,N/A,Peking University First Hospital,https://clinicaltrials.gov/ct2/show/NCT04334265,1,0,1,0,1,0,0,China,anluohuaxian
NCT04359810,4/21/2020,Interventional,Plasma Therapy of COVID-19 in Severely Ill Patients,Recruiting,Phase 2,Columbia University,https://clinicaltrials.gov/ct2/show/NCT04359810,1,0,1,0,3,1,0,United States|Brazil,convalescent plasma|plasma
NCT04338958,4/22/2020,Interventional,Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation,Recruiting,Phase 2,University of Jena,https://clinicaltrials.gov/ct2/show/NCT04338958,1,0,1,0,3,0,0,Germany,ruxolitinib
NCT04368338,4/28/2020,Observational,Lung Ultrasound to Diagnose COVID-19,Recruiting,NA,"Centre Hospitalier Universitaire, Amiens",https://clinicaltrials.gov/ct2/show/NCT04368338,2,0,2,0,1,0,0,France,pcr|lung ultrasound
NCT04322396,4/6/2020,Interventional,Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,Recruiting,Phase 2,"Chronic Obstructive Pulmonary Disease Trial Network, Denmark",https://clinicaltrials.gov/ct2/show/NCT04322396,2,0,2,0,3,0,0,Denmark,azithromycin|hydroxychloroquine|placebo
NCT04352517,3/16/2020,Observational,Influence Physical Activity Psychological Responses COVID-19 Pandemic,Recruiting,NA,University of Extremadura,https://clinicaltrials.gov/ct2/show/NCT04352517,1,0,1,0,1,0,0,Brazil|Chile|Uruguay,online survey
NCT04336254,4/6/2020,Interventional,Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients,Recruiting,Phase 1/Phase 2,Renmin Hospital of Wuhan University,https://clinicaltrials.gov/ct2/show/NCT04336254,1,0,1,0,0,0,0,China,mesenchymal stem cells|placebo|utooth btc)
NCT04369469,5/11/2020,Interventional,Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia,Recruiting,Phase 3,Alexion Pharmaceuticals,https://clinicaltrials.gov/ct2/show/NCT04369469,2,0,2,0,7,1,0,United States|France|Japan|Spain|United Kingdom,ravulizumab|best supportive care
NCT04354259,5/13/2020,Interventional,Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19,Recruiting,Phase 2,"University Health Network, Toronto",https://clinicaltrials.gov/ct2/show/NCT04354259,6,0,6,0,1,0,0,Canada,peginterferon|placebo
NCT04355364,4/21/2020,Interventional,Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE),Recruiting,Phase 3,Fondation Ophtalmologique Adolphe de Rothschild,https://clinicaltrials.gov/ct2/show/NCT04355364,1,0,1,0,7,0,0,France,pulmozyme|standard care
NCT04331574,3/10/2020,Observational [Patient Registry],Renin-Angiotensin System Inhibitors and COVID-19,Recruiting,NA,Societa Italiana dell'Ipertensione Arteriosa,https://clinicaltrials.gov/ct2/show/NCT04331574,2,0,2,0,0,0,0,Italy,"NA"
NCT04365959,3/20/2020,Observational,The Prone Position in Covid-19 Affected Patients,"Active, not recruiting",NA,University of Milano Bicocca,https://clinicaltrials.gov/ct2/show/NCT04365959,1,0,1,0,1,0,0,Italy,prone positioning
NCT04368156,4/20/2020,Interventional,Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,Recruiting,N/A,Hospital ClÃ­nico Universitario de Valencia,https://clinicaltrials.gov/ct2/show/NCT04368156,1,0,1,0,0,0,0,Spain,gammacoreâ® (vagus nerve stimulation)
NCT04348513,5/29/2020,Interventional,Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection,Recruiting,Phase 2,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,https://clinicaltrials.gov/ct2/show/NCT04348513,1,0,1,0,1,0,0,Greece,t3 solution|placebo
NCT04338672,4/5/2020,Observational,The Impact of the Covid-19 Outbreak on Emergency Room Attendances of Surgical Patients,Recruiting,NA,Sheba Medical Center,https://clinicaltrials.gov/ct2/show/NCT04338672,1,0,1,0,1,0,0,Israel,covid-19 pandemic
NCT04334291,3/23/2020,Observational [Patient Registry],"International COVID19 Clinical Evaluation Registry,",Recruiting,NA,"St Carlos Hospital, Madrid, Spain",https://clinicaltrials.gov/ct2/show/NCT04334291,5,0,5,0,2,0,0,Spain,observational
NCT04327531,3/26/2020,Observational,"Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study",Completed,NA,Kanuni Sultan Suleyman Training and Research Hospital,https://clinicaltrials.gov/ct2/show/NCT04327531,2,0,2,0,4,0,0,Turkey,turkish physicians
NCT04339608,4/2/2020,Observational,Max COVID19- Study,Recruiting,NA,Max Healthcare Insititute Limited,https://clinicaltrials.gov/ct2/show/NCT04339608,1,0,1,0,0,0,0,India,"NA"
NCT04380818,6/5/2020,Interventional,Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19,Recruiting,N/A,Grupo de InvestigaciÃ³n ClÃ­nica en OncologÃ­a Radioterapia,https://clinicaltrials.gov/ct2/show/NCT04380818,1,0,1,0,2,0,0,Spain,radiotherapy|hydroxychloroquine|lopinavir/ritonavir|tocilizumab|azithromycin|corticosteroid|heparin|oxygen|ritonavir|lopinavir
NCT04410562,5/13/2020,Interventional,Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy,Recruiting,Phase 3,Barcelona Institute for Global Health,https://clinicaltrials.gov/ct2/show/NCT04410562,1,0,1,0,1,0,0,Spain,hydroxychloroquine|placebo
NCT04307693,3/11/2020,Interventional,Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19),Terminated,Phase 2,Asan Medical Center,https://clinicaltrials.gov/ct2/show/NCT04307693,1,0,1,0,2,0,0,"Korea, Republic of",lopinavir/ritonavir|hydroxychloroquine|lopinavir|ritonavir
NCT04368676,6/25/2020,Interventional,Breath Regulation and Yogic Exercise An Online Therapy for Calm and Happiness,Recruiting,Early Phase 1,Lawson Health Research Institute,https://clinicaltrials.gov/ct2/show/NCT04368676,3,0,3,0,1,0,0,Canada,sudarshan kriya yoga (sky)|health enhancement program
NCT04390464,5/8/2020,Interventional,mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R),Recruiting,Phase 4,Cambridge University Hospitals NHS Foundation Trust,https://clinicaltrials.gov/ct2/show/NCT04390464,1,0,1,0,1,0,0,United Kingdom,ravulizumab|baricitinib|standard care
NCT04339816,5/13/2020,Interventional,Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial,Terminated,Phase 3,"Charles University, Czech Republic",https://clinicaltrials.gov/ct2/show/NCT04339816,1,0,1,0,3,0,0,Czechia,azithromycin|hydroxychloroquine|placebo
NCT04264533,2/14/2020,Interventional,Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia,Terminated,Phase 2,Zhongnan Hospital,https://clinicaltrials.gov/ct2/show/NCT04264533,1,0,1,0,2,0,0,China,vitamin c|water
NCT04321265,3/19/2020,Observational,Outcomes and Prognostic Factors in COVID-19,Recruiting,NA,"Heinrich-Heine University, Duesseldorf",https://clinicaltrials.gov/ct2/show/NCT04321265,1,0,1,0,4,0,0,Denmark|France|Germany|Norway,"NA"
NCT04471701,4/13/2020,Observational,Italian Web-based Cross-sectional Survey on COVID-19,Recruiting,NA,"Institute of Biomedical Technologies-National Research Council, Italy",https://clinicaltrials.gov/ct2/show/NCT04471701,1,0,1,0,1,0,0,Italy,environmental exposure/clinical features|environmental exposure|clinical features
NCT04311177,4/9/2020,Interventional,Losartan for Patients With COVID-19 Not Requiring Hospitalization,"Active, not recruiting",Phase 2,University of Minnesota,https://clinicaltrials.gov/ct2/show/NCT04311177,3,0,3,0,9,1,0,United States,losartan|placebo
NCT04335123,4/4/2020,Interventional,Study of Open Label Losartan in COVID-19,Completed,Phase 1,University of Kansas Medical Center,https://clinicaltrials.gov/ct2/show/NCT04335123,3,0,3,0,3,1,0,United States,losartan
NCT04312009,4/13/2020,Interventional,Losartan for Patients With COVID-19 Requiring Hospitalization,Recruiting,Phase 2,University of Minnesota,https://clinicaltrials.gov/ct2/show/NCT04312009,3,0,3,0,12,1,0,United States,losartan|placebo
NCT04283461,3/16/2020,Interventional,Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19),"Active, not recruiting",Phase 1,National Institute of Allergy and Infectious Diseases (NIAID),https://clinicaltrials.gov/ct2/show/NCT04283461,2,0,2,1,12,1,0,United States,mrna-1273
NCT04252274,1/30/2020,Interventional,Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19,Recruiting,Phase 3,Shanghai Public Health Clinical Center,https://clinicaltrials.gov/ct2/show/NCT04252274,1,0,1,0,2,0,0,China,darunavir/cobicistat|darunavir|cobicistat
NCT04251871,1/22/2020,Interventional,Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection,Recruiting,N/A,Beijing 302 Hospital,https://clinicaltrials.gov/ct2/show/NCT04251871,1,0,1,0,1,0,0,China,"conventional medicines (oxygen therapy, alfa interferon via aerosol inhalation,/lopinavir/ritonavir)/traditional chinese medicines (tcms) granules|conventional medicines (oxygen therapy, alfa interferon via aerosol inhalation,/lopinavir/ritonavir)|conventional medicines (oxygen therapy, alfa interferon via aerosol inhalation,|lopinavir|ritonavir|traditional chinese medicine"
NCT04370067,5/1/2020,Observational [Patient Registry],HUNgarian COronaVirus Disease-19 Epidemiological Research,Recruiting,NA,Semmelweis University Heart and Vascular Center,https://clinicaltrials.gov/ct2/show/NCT04370067,1,0,1,0,2,0,0,Hungary,"NA"
NCT04381936,3/19/2020,Interventional,Randomised Evaluation of COVID-19 Therapy,Recruiting,Phase 2/Phase 3,University of Oxford,https://clinicaltrials.gov/ct2/show/NCT04381936,3,3,6,0,6,0,0,United Kingdom,lopinavir/ritonavir|corticosteroid|hydroxychloroquine|azithromycin|convalescent plasma|tocilizumab|immunoglobulin|synthetic neutralising antibodies|aspirin|colchicine
NCT04368390,4/3/2020,Observational,Neuroradiolological Analysis of COVID-19 Patients,Recruiting,NA,"University Hospital, Strasbourg, France",https://clinicaltrials.gov/ct2/show/NCT04368390,1,0,1,0,2,0,0,France,"NA"
NCT04361474,5/18/2020,Interventional,Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity,"Active, not recruiting",Phase 3,Fondation Ophtalmologique Adolphe de Rothschild,https://clinicaltrials.gov/ct2/show/NCT04361474,1,0,1,0,4,0,0,France,budesonide|serum
NCT04279899,2/1/2020,Observational,The Investigation of the Neonates With or With Risk of COVID-19,Recruiting,NA,Children's Hospital of Fudan University,https://clinicaltrials.gov/ct2/show/NCT04279899,1,0,1,0,0,0,0,China,"NA"
NCT04403607,5/22/2020,Observational,Cardiac Imaging in SARS-CoV-2 (COVID-19),Recruiting,NA,NHS Greater Glasgow and Clyde,https://clinicaltrials.gov/ct2/show/NCT04403607,1,0,1,0,2,0,0,United Kingdom,"NA"
NCT04324606,4/23/2020,Interventional,A Study of a Candidate COVID-19 Vaccine (COV001),"Active, not recruiting",Phase 1/Phase 2,University of Oxford,https://clinicaltrials.gov/ct2/show/NCT04324606,4,0,4,1,12,0,0,United Kingdom,chadox1|menacwy|paracetamol
NCT04341389,4/12/2020,Interventional,A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector),"Active, not recruiting",Phase 2,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",https://clinicaltrials.gov/ct2/show/NCT04341389,1,0,1,1,3,0,0,China,adenovirus type 5 vector|placebo
NCT04322123,4/1/2020,Interventional,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),"Active, not recruiting",Phase 3,Hospital do Coracao,https://clinicaltrials.gov/ct2/show/NCT04322123,1,0,1,0,6,0,0,Brazil,hydroxychloroquine|hydroxychloroquine / azithromycin|azithromycin
NCT04441489,3/27/2020,Observational,Assessment of Lung Inflammation With FDG PET/CT in COVID-19,Completed,NA,Centre Hospitalier Princesse Grace,https://clinicaltrials.gov/ct2/show/NCT04441489,1,0,1,0,0,0,0,Monaco,"NA"
NCT04323644,1/1/2020,Observational,Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg),Recruiting,NA,University of Birmingham,https://clinicaltrials.gov/ct2/show/NCT04323644,1,0,1,0,1,0,0,Spain,surgery
NCT04368975,3/12/2020,Observational [Patient Registry],ARDS Caused by COVID-19,Recruiting,NA,Hospital Clinic of Barcelona,https://clinicaltrials.gov/ct2/show/NCT04368975,1,0,1,0,0,0,0,Spain,"NA"
NCT04393246,7/3/2020,Interventional,mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms,Recruiting,Phase 2/Phase 3,Cambridge University Hospitals NHS Foundation Trust,https://clinicaltrials.gov/ct2/show/NCT04393246,1,0,1,0,2,0,0,United Kingdom,edp1815|dapagliflozin|ambrisentan|standard care
NCT04363827,5/14/2020,Interventional,Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19),Recruiting,Phase 2,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,https://clinicaltrials.gov/ct2/show/NCT04363827,1,0,1,0,2,0,0,Italy,hydroxychloroquine
NCT04433910,8/30/2020,Interventional,A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19,"Active, not recruiting",Phase 2,Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen,https://clinicaltrials.gov/ct2/show/NCT04433910,1,0,1,0,3,0,0,Germany,convalescent plasma
NCT04355637,4/21/2020,Interventional,Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia,Recruiting,Phase 4,Fundacion Clinic per a la Recerca BiomÃ©dica,https://clinicaltrials.gov/ct2/show/NCT04355637,5,0,5,0,4,0,0,Argentina|Spain,budesonide
NCT04331470,4/4/2020,Interventional,Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19,Recruiting,Phase 2/Phase 3,Fasa University of Medical Sciences,https://clinicaltrials.gov/ct2/show/NCT04331470,5,0,5,0,2,0,0,"Iran, Islamic Republic of",levamisole / budesonide/formoterol|lopinavir/ritonavir / hydoxychloroquine|levamisole|budesonide|formoterol|lopinavir|ritonavir|hydroxychloroquine
NCT04377711,6/8/2020,Interventional,A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients,Recruiting,Phase 3,Covis Pharma S.Ã .r.l.,https://clinicaltrials.gov/ct2/show/NCT04377711,5,0,5,0,2,1,0,United States,ciclesonide|placebo
NCT04330586,4/1/2020,Interventional,A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19,Recruiting,Phase 2,Korea University Guro Hospital,https://clinicaltrials.gov/ct2/show/NCT04330586,5,0,5,0,1,0,0,"Korea, Republic of",ciclesonide
NCT04416399,7/16/2020,Interventional,STerOids in COVID-19 Study,Recruiting,Phase 2,University of Oxford,https://clinicaltrials.gov/ct2/show/NCT04416399,5,0,5,0,3,0,0,United Kingdom,budesonide
NCT04331509,3/23/2020,Observational,COVID-19 Symptom Tracker,Recruiting,NA,King's College London,https://clinicaltrials.gov/ct2/show/NCT04331509,1,0,1,0,2,1,0,United States|United Kingdom,no intervention
NCT04346186,4/15/2020,Observational,COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff,Enrolling by invitation,NA,Herlev Hospital,https://clinicaltrials.gov/ct2/show/NCT04346186,1,0,1,0,1,0,0,Denmark,igm/igg rapid test|igm|igg antibody test|igg
NCT04296643,4/1/2020,Interventional,Medical Masks vs N95 Respirators for COVID-19,Recruiting,N/A,McMaster University,https://clinicaltrials.gov/ct2/show/NCT04296643,1,0,1,0,1,0,0,Canada|Israel,medical mask|n95 respirator
NCT04392245,4/15/2020,Observational,Proctologic Practice and Covid-19,Completed,NA,Societa Italiana di Chirurgia ColoRettale,https://clinicaltrials.gov/ct2/show/NCT04392245,1,0,1,0,0,0,0,Italy,"NA"
NCT04338698,4/22/2020,Interventional,"Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT",Recruiting,Phase 3,University of Health Sciences Lahore,https://clinicaltrials.gov/ct2/show/NCT04338698,1,0,1,0,2,0,0,Pakistan,hydroxychloroquine|oseltamivir|azithromycin
NCT04401202,5/21/2020,Interventional,Nigella Sativa in COVID-19,Recruiting,Phase 2,King Abdulaziz University,https://clinicaltrials.gov/ct2/show/NCT04401202,1,0,1,0,0,0,0,Saudi Arabia,nigella sativa
NCT04401540,5/1/2020,Observational [Patient Registry],Characteristics of Neonatal Covid-19 in Turkey,Recruiting,NA,Recep Tayyip Erdogan University Training and Research Hospital,https://clinicaltrials.gov/ct2/show/NCT04401540,1,3,4,0,2,0,0,Turkey,"NA"
NCT04434131,4/28/2020,Interventional,Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19,Recruiting,Phase 2,University of New Mexico,https://clinicaltrials.gov/ct2/show/NCT04434131,15,0,15,0,0,1,0,United States,convalescent plasma
NCT04316949,3/20/2020,Observational,Predictors of Respiratory Failure in SARS-Cov-2 Infection,Recruiting,NA,University of Bologna,https://clinicaltrials.gov/ct2/show/NCT04316949,1,0,1,0,4,0,0,Italy,"NA"
NCT04368728,4/29/2020,Interventional,"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals",Recruiting,Phase 3,BioNTech SE,https://clinicaltrials.gov/ct2/show/NCT04368728,3,0,3,1,23,1,0,United States|Argentina|Brazil|Germany|South Africa|Turkey,bnt162b1|bnt162b2|placebo
NCT04343729,4/18/2020,Interventional,Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19,"Active, not recruiting",Phase 2,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,https://clinicaltrials.gov/ct2/show/NCT04343729,1,0,1,0,6,0,0,Brazil,methylprednisolone|placebo
NCT04394000,5/4/2020,Observational [Patient Registry],Impact of an Intensified Thromboprofylaxis Protocol in COVID-19,Completed,NA,Jessa Hospital,https://clinicaltrials.gov/ct2/show/NCT04394000,1,0,1,0,0,0,0,Belgium,thromboprofylaxis protocol|standard care
NCT04385095,3/16/2020,Interventional,Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection,Recruiting,Phase 2,Synairgen Research Ltd.,https://clinicaltrials.gov/ct2/show/NCT04385095,5,0,5,0,1,0,0,United Kingdom,sng001|placebo
NCT04343976,6/22/2020,Interventional,Pegylated Interferon Lambda Treatment for COVID-19,Enrolling by invitation,Phase 2,Massachusetts General Hospital,https://clinicaltrials.gov/ct2/show/NCT04343976,4,0,4,0,3,1,0,United States,peginterferon
NCT04344600,5/29/2020,Interventional,Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection,Recruiting,Phase 2,Johns Hopkins University,https://clinicaltrials.gov/ct2/show/NCT04344600,4,0,4,0,3,1,0,United States,peginterferon|saline
NCT04347993,3/27/2020,Observational [Patient Registry],"A Prospective ""Universal"" Observational Database for COVID-19",Recruiting,NA,Hackensack Meridian Health,https://clinicaltrials.gov/ct2/show/NCT04347993,2,0,2,0,1,1,0,United States,"NA"
NCT04345614,4/8/2020,Interventional,A Study of Auxora in Patients With Severe COVID-19 Pneumonia,Recruiting,Phase 2,"CalciMedica, Inc.",https://clinicaltrials.gov/ct2/show/NCT04345614,1,0,1,0,13,1,0,United States|Puerto Rico,auxora|placebo
NCT04352556,4/7/2020,Observational,COVID19-hematological Malignancies: the Italian Hematology Alliance,Recruiting,NA,Ospedale di Circolo - Fondazione Macchi,https://clinicaltrials.gov/ct2/show/NCT04352556,1,0,1,0,1,0,0,Italy,"NA"
NCT04375410,4/22/2020,Observational,Consequences of Intensified Handwash and Hand Disinfection Among Children During the COVID19 Pandemic,Enrolling by invitation,NA,Vendsyssel Hospital,https://clinicaltrials.gov/ct2/show/NCT04375410,1,0,1,0,0,0,0,Denmark,"NA"
NCT04381962,5/29/2020,Interventional,A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2),Recruiting,Phase 3,University of Oxford,https://clinicaltrials.gov/ct2/show/NCT04381962,1,0,1,0,1,0,0,United Kingdom,azithromycin
NCT04438629,3/26/2020,Observational,Evaluation of Immune Response in COVID-19 Patients,Recruiting,NA,Azienda Ospedaliera Universitaria Integrata Verona,https://clinicaltrials.gov/ct2/show/NCT04438629,1,0,1,0,1,0,0,Italy,covid-19 treatment
NCT04412057,6/9/2020,Interventional,Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury,Recruiting,Phase 2,Cerecor Inc,https://clinicaltrials.gov/ct2/show/NCT04412057,1,0,1,0,5,1,0,United States,cerc-002|placebo
NCT04292730,3/15/2020,Interventional,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Completed,Phase 3,Gilead Sciences,https://clinicaltrials.gov/ct2/show/NCT04292730,1,0,1,0,19,1,0,"Singapore|United States|China|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Netherlands|Spain|Sweden|Switzerland|Taiwan|United Kingdom",remdesivir|standard care
NCT04370288,4/19/2020,Interventional,Clinical Application of Methylene Blue for Treatment of Covid-19 Patients,Recruiting,Phase 1,Mashhad University of Medical Sciences,https://clinicaltrials.gov/ct2/show/NCT04370288,1,0,1,0,1,0,0,"Iran, Islamic Republic of",methylene blue/ vitamin c/n-acetyl cysteine
NCT04262921,2/8/2020,Observational,French COVID Cohort,Recruiting,NA,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",https://clinicaltrials.gov/ct2/show/NCT04262921,2,0,2,0,2,0,0,France,"NA"
NCT04337541,4/2/2020,Interventional,Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System,Completed,N/A,"Rigshospitalet, Denmark",https://clinicaltrials.gov/ct2/show/NCT04337541,2,0,2,0,1,0,0,Denmark,surgical facial mask
NCT04357730,5/14/2020,Interventional,Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection,Recruiting,Phase 2,Denver Health and Hospital Authority,https://clinicaltrials.gov/ct2/show/NCT04357730,1,0,1,0,8,1,0,United States,activase
NCT04252885,1/28/2020,Interventional,The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection,Completed,Phase 4,Guangzhou 8th People's Hospital,https://clinicaltrials.gov/ct2/show/NCT04252885,1,0,1,0,1,0,0,China,lopinavir/ritonavir|arbidol|lopinavir|ritonavir
NCT04395105,5/21/2020,Interventional,"Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial",Recruiting,Phase 3,Centro de EducaciÃ³n Medica e Investigaciones ClÃ­nicas Norberto Quirno,https://clinicaltrials.gov/ct2/show/NCT04395105,1,0,1,0,3,0,0,Argentina,dexamethasone
NCT04420741,6/15/2020,Interventional,Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure,Recruiting,Phase 2,"Rigshospitalet, Denmark",https://clinicaltrials.gov/ct2/show/NCT04420741,1,0,1,0,5,0,0,Denmark,iloprost|saline
NCT04378595,4/10/2020,Observational,Assessing Pediatric Food Insecurity During the COVID-19 Pandemic in Austin,Recruiting,NA,University of Texas at Austin,https://clinicaltrials.gov/ct2/show/NCT04378595,1,0,1,0,1,1,0,United States,during covid-19 pandemic|after covid-19 pandemic
NCT04378582,5/7/2020,Observational,Characteristics and Outcomes of Patients With COVID-19 Admitted to the ICU,Completed,NA,University of Sao Paulo General Hospital,https://clinicaltrials.gov/ct2/show/NCT04378582,1,0,1,0,3,0,0,Brazil,risk factors
NCT04327401,4/13/2020,Interventional,COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III,Terminated,Phase 3,Hospital Sirio-Libanes,https://clinicaltrials.gov/ct2/show/NCT04327401,1,0,1,0,5,0,0,Brazil,dexamethasone
NCT04305574,3/7/2020,Observational,Social Media Use During COVID-19,Completed,NA,Yale-NUS College,https://clinicaltrials.gov/ct2/show/NCT04305574,1,0,1,0,2,0,0,Singapore,use of social media during covid-19
NCT04368988,5/25/2020,Interventional,Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant,"Active, not recruiting",Phase 1/Phase 2,Novavax,https://clinicaltrials.gov/ct2/show/NCT04368988,3,0,3,1,5,1,0,United States|Australia,sars-cov-2 rs|sars-cov-2 rs/matrix-m1 adjuvant|placebo|adjuvant|21 - phase 2
NCT04338841,4/9/2020,Interventional,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection,Completed,N/A,"University Hospital, Angers",https://clinicaltrials.gov/ct2/show/NCT04338841,1,0,1,0,2,0,0,Belgium|France|Monaco,home-cov rule implementation
NCT04445935,6/28/2020,Interventional,Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial,Recruiting,Phase 4,Hamad Medical Corporation,https://clinicaltrials.gov/ct2/show/NCT04445935,1,0,1,0,0,0,0,Qatar,bivalirudin|standard care
NCT04436471,6/17/2020,Interventional,"An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" Vaccine Against COVID-19",Completed,Phase 1/Phase 2,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",https://clinicaltrials.gov/ct2/show/NCT04436471,2,0,2,1,3,0,0,Russian Federation,gam-covid-vac
NCT04437875,6/17/2020,Interventional,"An Open Study of the Safety, Tolerability and Immunogenicity of ""Gam-COVID-Vac Lyo"" Vaccine Against COVID-19",Completed,Phase 1/Phase 2,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",https://clinicaltrials.gov/ct2/show/NCT04437875,2,0,2,1,3,0,0,Russian Federation,gam-covid-vac lyo
NCT04333849,3/25/2020,Observational,Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19,Completed,NA,"University Hospital, Angers",https://clinicaltrials.gov/ct2/show/NCT04333849,1,0,1,0,2,0,0,France,"NA"
NCT04347681,4/18/2020,Interventional,Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19,Recruiting,Phase 2,King Fahad Specialist Hospital Dammam,https://clinicaltrials.gov/ct2/show/NCT04347681,1,0,1,0,3,0,0,Saudi Arabia,convalescent plasma
NCT04400799,6/15/2020,Interventional,Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19,Recruiting,Phase 3,University of Zurich,https://clinicaltrials.gov/ct2/show/NCT04400799,1,0,1,0,1,0,0,Switzerland,enoxaparin|0.4ml inj syringe 0.4ml
NCT04357808,4/13/2020,Interventional,Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID),"Active, not recruiting",Phase 2,FundaciÃ³n de InvestigaciÃ³n BiomÃ©dica - Hospital Universitario de La Princesa,https://clinicaltrials.gov/ct2/show/NCT04357808,1,0,1,0,2,0,0,Spain,sarilumab|standard care
NCT04396197,3/1/2020,Observational,Physical Activity Levels in COVID-19 Patients Admitted to Intensive Care,Completed,NA,University Hospital Birmingham NHS Foundation Trust,https://clinicaltrials.gov/ct2/show/NCT04396197,1,0,1,0,0,0,0,United Kingdom,physiotherapy
NCT04399317,5/28/2020,Interventional,Flow Controlled Ventilation in ARDS Associated With COVID-19,Recruiting,N/A,Hamad Medical Corporation,https://clinicaltrials.gov/ct2/show/NCT04399317,1,0,1,0,1,0,0,Qatar,flow controlled ventilation (evone-ventilator)
NCT04327206,3/30/2020,Interventional,BCG Vaccination to Protect Healthcare Workers Against COVID-19,Recruiting,Phase 3,Murdoch Childrens Research Institute,https://clinicaltrials.gov/ct2/show/NCT04327206,1,0,1,1,9,0,0,Australia|Netherlands|Spain|United Kingdom,bcg|saline
NCT04352959,4/27/2020,Interventional,COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses,Recruiting,N/A,Claude Bernard University,https://clinicaltrials.gov/ct2/show/NCT04352959,3,0,3,0,2,0,0,France,mouthrinse with bãªta-cyclodextrin/citrox|mouthrinse without bãªta-cyclodextrin/citrox|mouthrinse with bãªta-cyclodextrin|citrox|mouthrinse without bãªta-cyclodextrin
NCT04364802,4/29/2020,Interventional,COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients,Recruiting,Phase 2,University of Kentucky,https://clinicaltrials.gov/ct2/show/NCT04364802,2,0,2,0,2,1,0,United States,povidone/iodine|gargle
NCT04373291,5/18/2020,Interventional,Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic,Recruiting,Phase 3,Bandim Health Project,https://clinicaltrials.gov/ct2/show/NCT04373291,1,0,1,1,3,0,0,Denmark,bcg-denmark|saline
NCT04367129,4/14/2020,Observational,Electrocardiogram Analysis in COVID-19 Patients,Recruiting,NA,University Hospital of Ferrara,https://clinicaltrials.gov/ct2/show/NCT04367129,1,1,2,0,0,0,0,Italy,ecg
NCT04439084,3/6/2020,Observational,COVID-19 in Patients With Chronic Liver Diseases,Enrolling by invitation,NA,Stanford University,https://clinicaltrials.gov/ct2/show/NCT04439084,1,0,1,0,1,1,0,United States,prospective chart review
NCT04343261,4/10/2020,Interventional,Convalescent Plasma in the Treatment of COVID 19,Completed,Phase 2,Saint Francis Care,https://clinicaltrials.gov/ct2/show/NCT04343261,16,2,18,0,9,1,1,United States,convalescent plasma
NCT04335162,2/28/2020,Observational,Cardiovascular Complications and COVID-19 (CovCardioVasc-Study),Recruiting,NA,Centre Hospitalier Universitaire de Nice,https://clinicaltrials.gov/ct2/show/NCT04335162,1,0,1,0,4,0,0,France,"NA"
NCT04318418,3/23/2020,Observational,"ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19",Completed,NA,Neuromed IRCCS,https://clinicaltrials.gov/ct2/show/NCT04318418,1,0,1,0,1,0,0,Italy,"NA"
NCT04321928,4/1/2020,Interventional,Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary,Recruiting,N/A,University of Pecs,https://clinicaltrials.gov/ct2/show/NCT04321928,1,0,1,0,2,0,0,Hungary,personalized health education|general health education
NCT04394416,6/2/2020,Interventional,Trial of Imatinib for Hospitalized Adults With COVID-19,Recruiting,Phase 3,"University of Maryland, Baltimore",https://clinicaltrials.gov/ct2/show/NCT04394416,2,0,2,0,1,1,0,United States,imatinib|placebo
NCT04329923,4/9/2020,Interventional,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Terminated,Phase 2,University of Pennsylvania,https://clinicaltrials.gov/ct2/show/NCT04329923,1,1,2,0,7,1,1,United States,hydroxychloroquine|placebo
NCT04377815,4/23/2020,Observational,Finding Out if COVID-19 Infection Can be pREdicted by ChAnges in Smell and/or Taste,Completed,NA,"University College, London",https://clinicaltrials.gov/ct2/show/NCT04377815,1,0,1,0,1,0,0,United Kingdom,general public cohort
NCT04352764,3/27/2020,Observational [Patient Registry],ANTIBODY BASED TESTS FOR SARSCoV-2 COVID-19) - Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings,Recruiting,NA,Texas Cardiac Arrhythmia Research Foundation,https://clinicaltrials.gov/ct2/show/NCT04352764,1,0,1,0,2,1,0,United States,igm/igg rapid test|igg antibody test|igm
NCT04333420,3/31/2020,Interventional,"Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia",Recruiting,Phase 2/Phase 3,InflaRx GmbH,https://clinicaltrials.gov/ct2/show/NCT04333420,1,0,1,0,5,0,0,Germany|Netherlands,soc / ifx-1|soc / placebo|standard care|ifx-1|placebo
NCT04384926,3/30/2020,Observational,Outcomes of Elective Cancer Surgery During the COVID-19 Pandemic Crisis,Recruiting,NA,University of Birmingham,https://clinicaltrials.gov/ct2/show/NCT04384926,1,0,1,0,0,0,0,Spain,elective cancer surgery
NCT04358029,4/9/2020,Observational,Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19),Recruiting,NA,Icahn School of Medicine at Mount Sinai,https://clinicaltrials.gov/ct2/show/NCT04358029,1,0,1,0,1,1,0,United States,"NA"
NCT04323839,3/20/2020,Observational [Patient Registry],COVID-19 PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY),Enrolling by invitation,NA,"University of California, San Francisco",https://clinicaltrials.gov/ct2/show/NCT04323839,1,0,1,0,4,1,0,United States,pregnant women under investigation for coronavirus/diagnosed with covid-19|postpartum women under investigation for coronavirus/diagnosed with covid-19|pregnant women under investigation for coronavirus|diagnosed with covid-19|postpartum
NCT04317092,3/19/2020,Interventional,Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),"Active, not recruiting",Phase 2,"National Cancer Institute, Naples",https://clinicaltrials.gov/ct2/show/NCT04317092,3,0,3,0,3,0,0,Italy,tocilizumab
NCT04307459,3/19/2020,Observational,Acute Respiratory Failure and COVID-19 in Real Life,Recruiting,NA,University of Milan,https://clinicaltrials.gov/ct2/show/NCT04307459,1,0,1,0,3,0,0,Italy,SOP
NCT04441424,4/3/2020,Interventional,Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients,Completed,N/A,Alkarkh Health Directorate-Baghdad,https://clinicaltrials.gov/ct2/show/NCT04441424,14,0,14,0,1,0,0,Iraq,convalescent plasma|hydroxychloroquine / azithromycin
NCT04342182,4/8/2020,Interventional,Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study),"Active, not recruiting",Phase 2/Phase 3,Erasmus Medical Center,https://clinicaltrials.gov/ct2/show/NCT04342182,14,0,14,0,11,0,0,Netherlands,convalescent plasma
NCT04357106,4/13/2020,Interventional,COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma,Recruiting,Phase 2,Centro de HematologÃ­a y Medicina Interna,https://clinicaltrials.gov/ct2/show/NCT04357106,14,0,14,0,0,0,0,Mexico,convalescent plasma
NCT04340050,4/10/2020,Interventional,COVID-19 Convalescent Plasma,Completed,Early Phase 1,University of Chicago,https://clinicaltrials.gov/ct2/show/NCT04340050,14,0,14,0,4,1,0,United States,convalescent plasma
NCT04507282,5/15/2020,Observational,Eosinophil and Anticoagulation in COVID-19 Patients,Completed,NA,Bursa Postgraduate Hospital,https://clinicaltrials.gov/ct2/show/NCT04507282,1,0,1,0,1,0,0,Turkey,lmwh
NCT04555096,9/9/2020,Interventional,A Trial of GC4419 in Patients With Critical Illness Due to COVID-19,Recruiting,Phase 2,"Galera Therapeutics, Inc.",https://clinicaltrials.gov/ct2/show/NCT04555096,1,0,1,0,3,1,0,United States,gc4419|placebo
NCT04356495,7/29/2020,Interventional,Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation,Recruiting,Phase 2/Phase 3,"University Hospital, Bordeaux",https://clinicaltrials.gov/ct2/show/NCT04356495,1,0,1,0,6,0,0,France,vitamins|telmisartan|ciclesonide
NCT04445467,8/1/2020,Interventional,An Adaptive Clinical Trial of Antivirals for COVID-19 Infection,Recruiting,Phase 2,Bayside Health,https://clinicaltrials.gov/ct2/show/NCT04445467,1,0,1,0,1,0,0,Australia,favipiravir
NCT04314232,3/18/2020,Observational,Mechanisms for Covid-19 Disease Complications,Recruiting,NA,"University Hospital, Akershus",https://clinicaltrials.gov/ct2/show/NCT04314232,1,0,1,0,1,0,0,Norway,"NA"
NCT04448717,6/16/2020,Observational,Longitudinal Study of Seroprevalence of SARS-CoV-2 Antibodies and Development of Immunity in School Children,Recruiting,NA,University of Zurich,https://clinicaltrials.gov/ct2/show/NCT04448717,1,0,1,0,1,0,0,Switzerland,covid-19 antibody testing
NCT04343963,4/4/2020,Interventional,Pyridostigmine in Severe SARS-CoV-2 Infection,Recruiting,Phase 2/Phase 3,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,https://clinicaltrials.gov/ct2/show/NCT04343963,1,0,1,0,2,0,0,Mexico,pyridostigmine bromide|placebo
NCT04423770,6/8/2020,Observational,COVID-19 Related Health and Infection Control Practices Among Dentists,"Active, not recruiting",NA,American Dental Association,https://clinicaltrials.gov/ct2/show/NCT04423770,1,0,1,0,3,1,0,United States,no intervention
NCT04323592,3/23/2020,Observational [Patient Registry],Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Completed,NA,University of Trieste,https://clinicaltrials.gov/ct2/show/NCT04323592,1,0,1,0,6,0,1,Italy,methylprednisolone|standard care
NCT04411459,2/1/2020,Observational,Risk Factors for Prolonged Invasive Mechanical Ventilation in COVID-19 Acute Respiratory Distress Syndrome,Completed,NA,Azienda Usl di Bologna,https://clinicaltrials.gov/ct2/show/NCT04411459,2,6,8,0,2,0,0,Italy,invasive mechanical ventilation
NCT04346355,3/31/2020,Interventional,Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Terminated,Phase 2,Azienda UnitÃ  Sanitaria Locale Reggio Emilia,https://clinicaltrials.gov/ct2/show/NCT04346355,1,0,1,0,2,0,0,Italy,tocilizumab
NCT04331808,3/30/2020,Interventional,CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),"Active, not recruiting",Phase 2,Assistance Publique - HÃ´pitaux de Paris,https://clinicaltrials.gov/ct2/show/NCT04331808,1,0,1,0,2,0,0,France,tocilizumab
NCT04436276,7/15/2020,Interventional,A Study of Ad26.COV2.S in Adults (COVID-19),Recruiting,Phase 1/Phase 2,Janssen Vaccines & Prevention B.V.,https://clinicaltrials.gov/ct2/show/NCT04436276,2,0,2,0,7,1,0,United States|Belgium,ad26.cov2.s|placebo
NCT04356937,4/20/2020,Interventional,Efficacy of Tocilizumab on Patients With COVID-19,Completed,Phase 3,Massachusetts General Hospital,https://clinicaltrials.gov/ct2/show/NCT04356937,1,0,1,0,4,1,0,United States,tocilizumab|placebo
NCT04416100,4/29/2020,Observational,Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection (COVID-19),Recruiting,NA,Medical University Innsbruck,https://clinicaltrials.gov/ct2/show/NCT04416100,1,0,1,0,1,0,0,Austria,pulmonary function tests|imaging|blood sample
NCT04282135,2/15/2020,Observational,Detection of Influenza or SARS-CoV-2 Infection by IMS of Nasal Air Sampling,Completed,NA,Klinikum Bayreuth GmbH,https://clinicaltrials.gov/ct2/show/NCT04282135,1,0,1,0,1,0,0,Germany,mcc ims
NCT04374526,5/27/2020,Interventional,Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.,Recruiting,Phase 2/Phase 3,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,https://clinicaltrials.gov/ct2/show/NCT04374526,1,0,1,0,2,0,0,Italy,convalescent plasma
NCT04290780,3/9/2020,Observational,COVID-19 - Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus,Recruiting,NA,Hospices Civils de Lyon,https://clinicaltrials.gov/ct2/show/NCT04290780,1,0,1,0,5,0,0,France,nosocomial|hospital acquired infection
NCT04403477,5/20/2020,Interventional,Convalescent Plasma Therapy in Severe COVID-19 Infection,Recruiting,Phase 2,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",https://clinicaltrials.gov/ct2/show/NCT04403477,1,0,1,0,0,0,0,Bangladesh,convalescent plasma
NCT04389840,6/3/2020,Interventional,Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure,Recruiting,Phase 2/Phase 3,Chimerix,https://clinicaltrials.gov/ct2/show/NCT04389840,1,0,1,0,10,1,0,United States,dociparastat sodium|placebo
NCT04344197,4/2/2020,Observational,"Surgery During Covid-19: The Role of Asymptomatic Patients, a Survey",Completed,NA,University of Rome Tor Vergata,https://clinicaltrials.gov/ct2/show/NCT04344197,1,0,1,0,1,0,0,Italy,global survey
NCT04328493,4/7/2020,Interventional,The Vietnam Chloroquine Treatment on COVID-19,Recruiting,Phase 2,"Oxford University Clinical Research Unit, Vietnam",https://clinicaltrials.gov/ct2/show/NCT04328493,1,0,1,0,3,0,0,Vietnam,chloroquine
NCT04427501,11/17/2019,Interventional,A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness,Recruiting,Phase 2/Phase 3,Eli Lilly and Company,https://clinicaltrials.gov/ct2/show/NCT04427501,2,0,2,0,29,1,0,United States|Puerto Rico,ly3819253|ly3832479|placebo
NCT04407156,6/1/2020,Observational,Epidemiology of Acute Kidney Injury in COVID19 Disease in United Kingdom,Completed,NA,University Hospitals of Derby and Burton NHS Foundation Trust,https://clinicaltrials.gov/ct2/show/NCT04407156,1,0,1,0,2,0,0,United Kingdom,acute kidney injury
NCT04392973,5/21/2020,Interventional,FAvipiravir and HydroxyChloroquine Combination Therapy,Recruiting,N/A,King Abdullah International Medical Research Center,https://clinicaltrials.gov/ct2/show/NCT04392973,1,0,1,0,2,0,0,Saudi Arabia,favipiravir/hydroxychloroquine|favipiravir|hydroxychloroquine
NCT04521309,6/19/2020,Interventional,SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients,Recruiting,Phase 1,Dow University of Health Sciences,https://clinicaltrials.gov/ct2/show/NCT04521309,1,0,1,0,2,0,0,Pakistan,sars-cov-2 antibody based ivig therapy
NCT04336345,4/1/2020,Observational [Patient Registry],Outcomes of Patients With COVID-19 in the Intensive Care Unit,Completed,NA,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,https://clinicaltrials.gov/ct2/show/NCT04336345,1,0,1,0,6,0,0,Mexico,"NA"
NCT04492475,8/4/2020,Interventional,Adaptive COVID-19 Treatment Trial 3 (ACTT-3),"Active, not recruiting",Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),https://clinicaltrials.gov/ct2/show/NCT04492475,2,0,2,0,28,1,0,"United States|Japan|Korea, Republic of|Mexico|Singapore",interferon|placebo|remdesivir
NCT04401579,5/8/2020,Interventional,Adaptive COVID-19 Treatment Trial 2 (ACTT-2),Completed,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),https://clinicaltrials.gov/ct2/show/NCT04401579,3,0,3,0,13,1,0,"United States|Denmark|Japan|Korea, Republic of|Mexico|Singapore|Spain|United Kingdom",placebo|remdesivir|baricitinib
NCT04349202,4/10/2020,Observational,Beaumont Health Large-scale Automated Serologic Testing for COVID-19,Recruiting,NA,William Beaumont Hospitals,https://clinicaltrials.gov/ct2/show/NCT04349202,1,0,1,0,2,1,0,United States,euroimmun assay
NCT04557605,9/14/2020,Interventional,Effects of a Face Mask on Oxygenation During Exercise,Completed,N/A,University of Saskatchewan,https://clinicaltrials.gov/ct2/show/NCT04557605,1,0,1,0,1,0,0,Canada,progressive cycling exercise test to exhaustion
NCT04351152,4/30/2020,Interventional,Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19,Recruiting,Phase 3,"Humanigen, Inc.",https://clinicaltrials.gov/ct2/show/NCT04351152,1,0,1,0,10,1,0,United States,lenzilumab|standard care
NCT04428099,1/13/2020,Interventional,Healthy Lifestyle Promotion as Adjunctive Teletherapy for Treatment-resistant Major Depression,Recruiting,N/A,University of the Balearic Islands,https://clinicaltrials.gov/ct2/show/NCT04428099,1,0,1,0,0,0,0,Spain,lifestyle change promotion program|mindfulness|information
NCT04412538,5/15/2020,Interventional,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19,Recruiting,Phase 1/Phase 2,Chinese Academy of Medical Sciences,https://clinicaltrials.gov/ct2/show/NCT04412538,1,0,1,1,1,0,0,China,inactivated sars-cov-2 vaccine|medium dosage inactivated sars-cov-2 vaccine on a 0-/28-day schedule|medium dosage inactivated sars-cov-2 vaccine on a 0-/14-day schedule|placebo|28-day schedule|14-day schedule|medium dosage inactivated sars-cov-2 vaccine on a 0-
NCT04346342,3/6/2020,Observational,PRactice of VENTilation in COVID-19 Patients (PRoVENT-COVID),Completed,NA,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),https://clinicaltrials.gov/ct2/show/NCT04346342,2,0,2,0,3,0,0,Netherlands,"NA"
NCT04486404,4/1/2020,Observational,"Needs, Perceptions and Acute Stress of Healtcare Workers Caring for COVID-19 Patients in South America",Enrolling by invitation,NA,Universidad Miguel Hernandez de Elche,https://clinicaltrials.gov/ct2/show/NCT04486404,1,0,1,0,3,0,0,Argentina|Chile|Colombia|Ecuador|Spain,online survey
NCT04366882,4/14/2020,Interventional,Minimal Invasive Autopsies to Investigate Changes in Deceased COVID-19 Patients,Recruiting,N/A,Jessa Hospital,https://clinicaltrials.gov/ct2/show/NCT04366882,1,0,1,0,0,0,0,Belgium,ct-scan
NCT04487990,6/29/2020,Interventional,CoV-Hep Study: Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19,Recruiting,N/A,University of Sao Paulo General Hospital,https://clinicaltrials.gov/ct2/show/NCT04487990,1,0,1,0,0,0,0,Brazil,heparin
NCT04395144,5/15/2020,Interventional,COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss,Recruiting,N/A,HÃ´pital de Verdun,https://clinicaltrials.gov/ct2/show/NCT04395144,4,0,4,0,2,0,0,Canada,prone positioning|standard care
NCT04391140,5/13/2020,Interventional,Prone Positioning and High-flow Nasal Cannula in COVID-19 Induced ARDS,Recruiting,N/A,Hospital Universitari Vall d'Hebron Research Institute,https://clinicaltrials.gov/ct2/show/NCT04391140,4,0,4,0,2,0,0,Spain,prone positioning
NCT04347941,7/11/2020,Interventional,Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE,Recruiting,N/A,University College Hospital Galway,https://clinicaltrials.gov/ct2/show/NCT04347941,4,0,4,0,1,0,0,Ireland,prone positioning|standard care
NCT04358939,4/27/2020,Interventional,Prone Position in Patients on High-flow Nasal Oxygen Therapy for COVID-19 (HIGH-PRONE-COVID-19),Recruiting,N/A,"University Hospital, Tours",https://clinicaltrials.gov/ct2/show/NCT04358939,4,0,4,0,7,0,0,France,prone positioning
NCT04386395,3/30/2020,Observational,Immune Changes in Severe COVID-19 Pulmonary Infections,"Active, not recruiting",NA,"Central Hospital, Nancy, France",https://clinicaltrials.gov/ct2/show/NCT04386395,1,0,1,0,0,0,0,France,"NA"
NCT04342663,4/10/2020,Interventional,"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection",Completed,Phase 2,Washington University School of Medicine,https://clinicaltrials.gov/ct2/show/NCT04342663,8,0,8,0,5,1,0,United States,fluvoxamine|placebo
NCT04412655,5/5/2020,Observational,Primary Angioplasty for STEMI During COVID-19 Pandemic (ISACS-STEMI COVID-19) Registry,"Active, not recruiting",NA,"UniversitÃ  degli Studi del Piemonte Orientale ""Amedeo Avogadro""",https://clinicaltrials.gov/ct2/show/NCT04412655,2,0,2,0,1,0,0,Italy,percutaneous coronary revascularization for stemi
NCT04364022,4/23/2020,Interventional,Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland,Recruiting,Phase 3,"University Hospital, Geneva",https://clinicaltrials.gov/ct2/show/NCT04364022,1,0,1,0,1,0,0,Switzerland,lopinavir/ritonavir|lopinavir|ritonavir
NCT04435041,6/1/2020,Observational [Patient Registry],Remote-by-Default Care in the COVID-19 Pandemic,"Active, not recruiting",NA,University of Oxford,https://clinicaltrials.gov/ct2/show/NCT04435041,2,0,2,0,0,0,0,United Kingdom,"NA"
NCT04459247,6/15/2020,Interventional,"Short Term, High Dose Vitamin D Supplementation for COVID-19","Active, not recruiting",N/A,Postgraduate Institute of Medical Education and Research,https://clinicaltrials.gov/ct2/show/NCT04459247,1,0,1,0,1,0,0,India,vitamin d
NCT04374149,4/30/2020,Interventional,Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS,"Active, not recruiting",Phase 2,Prisma Health-Upstate,https://clinicaltrials.gov/ct2/show/NCT04374149,1,0,1,0,1,1,0,United States,therapeutic plasma exchange (tpe)|ruxolitinib
NCT04487964,1/1/2020,Interventional,Complementary Intervention for COVID-19,Recruiting,N/A,Egyptian Biomedical Research Network,https://clinicaltrials.gov/ct2/show/NCT04487964,1,0,1,0,1,0,0,Egypt,licorice extract
NCT04468893,5/20/2020,Interventional,Online Positive Psychology Intervention for Depression and Anxiety Due to COVID-19,Recruiting,N/A,Universidad Internacional de Valencia,https://clinicaltrials.gov/ct2/show/NCT04468893,1,6,7,0,1,0,0,Mexico,online intervention mental health covid-19
NCT04455360,10/1/2020,Interventional,Early EMDR Following Covid-19 Critical Illness: A Feasibility Trial,Recruiting,N/A,University Hospital Southampton NHS Foundation Trust,https://clinicaltrials.gov/ct2/show/NCT04455360,1,0,1,0,1,0,0,United Kingdom,eye movement desensitisation/reprocessing recent traumatic event protocol|eye movement desensitisation|reprocessing recent traumatic event protocol
NCT04328467,4/6/2020,Interventional,Pre-exposure Prophylaxis for SARS-Coronavirus-2,"Active, not recruiting",Phase 3,University of Minnesota,https://clinicaltrials.gov/ct2/show/NCT04328467,1,0,1,0,5,1,0,United States,hydroxychloroquine|placebo
NCT04341922,5/9/2020,Interventional,A Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic,"Active, not recruiting",N/A,Karolinska Institutet,https://clinicaltrials.gov/ct2/show/NCT04341922,1,0,1,0,5,0,0,Sweden,internet-delivered cognitive behavior therapy (icbt) for dysfunctional worry related to the covid-19 pandemic
NCT04382755,5/22/2020,Interventional,ZilucoplanÂ® in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure,"Active, not recruiting",Phase 2,"University Hospital, Ghent",https://clinicaltrials.gov/ct2/show/NCT04382755,1,0,1,0,2,0,0,Belgium,zilucoplanâ®|placebo
NCT04352608,4/16/2020,Interventional,Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19),"Active, not recruiting",Phase 1/Phase 2,"Sinovac Biotech Co., Ltd",https://clinicaltrials.gov/ct2/show/NCT04352608,1,0,1,1,3,0,0,China,inactivated sars-cov-2 vaccine|placebo
NCT04400838,5/28/2020,Interventional,Investigating a Vaccine Against COVID-19,Recruiting,Phase 2/Phase 3,University of Oxford,https://clinicaltrials.gov/ct2/show/NCT04400838,4,0,4,1,9,0,0,United Kingdom,chadox1|menacwy|menacwy vaccine|two dose menacwy vaccine min. 4 weeks apart|two dose chadox1 ncov-19/covishield 0.5ml|two dose chadox1 ncov-19/covishield 0.25ml/0.5ml|2.2x10^10vp (qpcr) boost|boost|two dose chadox1 ncov-19|covishield 0.5ml|covishield 0.25ml|0.5ml
NCT04406090,4/1/2020,Observational,Endovascular Thrombectomy in COVID-19 Infected Patients,Completed,NA,"University Hospital, Montpellier",https://clinicaltrials.gov/ct2/show/NCT04406090,1,0,1,0,1,0,0,France,mechanical trombectomy
NCT04412304,3/6/2020,Observational,Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients,Completed,NA,Karolinska Institutet,https://clinicaltrials.gov/ct2/show/NCT04412304,1,0,1,0,2,0,0,Sweden,tinzaparin/dalteparin|tinzaparin|dalteparin
NCT04449380,11/2/2020,Interventional,Clinical Study for the Treatment With Interferon-ÃŸ-1a (IFNÃŸ-1a) of COVID-19 Patients,Recruiting,Phase 2,IRCCS San Raffaele,https://clinicaltrials.gov/ct2/show/NCT04449380,1,0,1,0,4,0,0,Italy,interferon-ãÿ-1a|standard care
NCT04495816,7/15/2020,Interventional,COVID-19 Anosmia Study,Recruiting,Phase 2,Icahn School of Medicine at Mount Sinai,https://clinicaltrials.gov/ct2/show/NCT04495816,1,0,1,0,2,1,0,United States,omega-3|placebo/control|placebo|control
NCT04477655,5/3/2020,Interventional,Prone Positioning in Non-intubated Patients With COVID-19 Associated Acute Respiratory Failure,Recruiting,N/A,Hospital Civil de Guadalajara,https://clinicaltrials.gov/ct2/show/NCT04477655,1,0,1,0,2,0,0,Mexico,prone positioning|oxygen
NCT04438070,4/10/2020,Interventional,COVID Screening Strategies in Homeless Shelters,Recruiting,N/A,St. Joseph's Healthcare Hamilton,https://clinicaltrials.gov/ct2/show/NCT04438070,1,0,1,0,0,0,0,Canada,covid-19 swab
NCT04357535,5/10/2020,Observational,Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives,Completed,NA,King Faisal Specialist Hospital & Research Center,https://clinicaltrials.gov/ct2/show/NCT04357535,1,0,1,0,8,0,0,Saudi Arabia,angiotensin-converting enzyme inhibitors (ace-i)/angiotensin ii receptor blockers (arb)|ace inhibitor|arb blocker
NCT04383535,5/15/2020,Interventional,Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia,Completed,N/A,Hospital Italiano de Buenos Aires,https://clinicaltrials.gov/ct2/show/NCT04383535,1,1,2,0,4,0,0,Argentina,convalescent plasma|placebo
NCT04529525,8/19/2020,Interventional,Ivermectin to Prevent Hospitalizations in COVID-19,Recruiting,Phase 2/Phase 3,Instituto de CardiologÃ­a de Corrientes,https://clinicaltrials.gov/ct2/show/NCT04529525,1,12,13,0,3,0,0,Argentina,ivermectin|placebo
NCT04341142,4/9/2020,Interventional,Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER,Recruiting,N/A,Hospices Civils de Lyon,https://clinicaltrials.gov/ct2/show/NCT04341142,1,0,1,0,5,0,0,France,serology test
NCT04380987,5/4/2020,Observational,Luxembourg Cohort of Positive Patients for COVID-19: a Stratification Study to Predict Patient Prognosis,Recruiting,NA,Luxembourg Institute of Health,https://clinicaltrials.gov/ct2/show/NCT04380987,1,0,1,0,0,0,0,Luxembourg,biological samples
NCT04344119,4/9/2020,Observational,Assessment of Chilbains Occuring During Covid-19 Infection,Recruiting,NA,Centre Hospitalier Universitaire de Nice,https://clinicaltrials.gov/ct2/show/NCT04344119,1,0,1,0,2,0,0,France,"NA"
NCT04430608,5/25/2020,Interventional,Remote Continues Glucose Monitoring During the COVID-19 Pandemic in Quarantined Hospitalized Patients,Recruiting,N/A,Nordsjaellands Hospital,https://clinicaltrials.gov/ct2/show/NCT04430608,1,0,1,0,0,0,0,Denmark,dexcom
NCT04244591,1/26/2020,Interventional,Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure,Completed,Phase 2/Phase 3,Peking Union Medical College Hospital,https://clinicaltrials.gov/ct2/show/NCT04244591,7,0,7,0,6,0,0,China,methylprednisolone|standard care
NCT04348695,4/12/2020,Interventional,Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.,Recruiting,Phase 2,FundaciÃ³n de investigaciÃ³n HM,https://clinicaltrials.gov/ct2/show/NCT04348695,7,0,7,0,1,0,0,Spain,ruxolitinib|standard care|simvastatin
NCT04359329,4/20/2020,Interventional,Estrogen Patch for COVID-19 Symptoms,Recruiting,Phase 2,Stony Brook University,https://clinicaltrials.gov/ct2/show/NCT04359329,7,0,7,0,0,1,0,United States,estradiol
NCT04304313,2/9/2020,Interventional,A Pilot Study of Sildenafil in COVID-19,Recruiting,Phase 3,Tongji Hospital,https://clinicaltrials.gov/ct2/show/NCT04304313,7,0,7,0,1,0,0,China,sildenafil citrate
NCT04321174,4/17/2020,Interventional,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,Recruiting,Phase 3,"St. Michael's Hospital, Toronto",https://clinicaltrials.gov/ct2/show/NCT04321174,7,0,7,0,1,0,0,Canada,lopinavir/ritonavir|lopinavir|ritonavir
NCT04429854,5/2/2020,Interventional,Donated Antibodies Working Against nCoV,Recruiting,Phase 2,Universitaire Ziekenhuizen Leuven,https://clinicaltrials.gov/ct2/show/NCT04429854,1,0,1,0,0,0,0,Belgium,convalescent plasma|standard care
NCT04447534,6/23/2020,Interventional,Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19,Recruiting,Phase 3,Tanta University,https://clinicaltrials.gov/ct2/show/NCT04447534,1,0,1,0,3,0,0,Egypt,chloroquine|zinc
NCT04444661,6/10/2020,Observational,Effects of COVID-19 Induced Deconditioning After Long-term High Intensity Resistance Exercise,"Active, not recruiting",NA,University of Erlangen-NÃ¼rnberg Medical School,https://clinicaltrials.gov/ct2/show/NCT04444661,1,0,1,0,3,0,0,Germany,"NA"
NCT04349592,4/14/2020,Interventional,Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19,Recruiting,N/A,Hamad Medical Corporation,https://clinicaltrials.gov/ct2/show/NCT04349592,1,0,1,0,1,0,0,Qatar,hydroxychloroquine|azithromycin|placebo
NCT04386083,6/10/2020,Observational,Neurologic Manifestations of COVID-19,Recruiting,NA,University of the Philippines,https://clinicaltrials.gov/ct2/show/NCT04386083,1,0,1,0,1,0,0,Philippines,"NA"
NCT04361877,3/30/2020,Observational,Cardiovascular Prevention During COVID-19 Pandemic Lockdown in Young Adults (COLA Trial),Recruiting,NA,Klinikum der Universitaet Muenchen,https://clinicaltrials.gov/ct2/show/NCT04361877,1,0,1,0,1,0,0,Germany,"NA"
NCT04445324,8/25/2020,Interventional,Effects of Online and Recovery-oriented Peer Support Groups Facilitated by Peer Support Workers in Times of COVID-19,"Active, not recruiting",N/A,Centre de Recherche de l'Institut Universitaire en santÃ© Mentale de MontrÃ©al,https://clinicaltrials.gov/ct2/show/NCT04445324,1,0,1,0,4,0,0,Canada,"online support group|control|or psychotherapy, n=10)"
NCT04405726,3/27/2020,Observational,Prognostic Factors of COVID19,Recruiting,NA,"University Hospital, Strasbourg, France",https://clinicaltrials.gov/ct2/show/NCT04405726,1,0,1,0,2,0,0,France,"NA"
NCT04402970,6/19/2020,Interventional,Dornase Alfa for ARDS in Patients With SARS-CoV-2,Recruiting,Phase 3,University of Missouri-Columbia,https://clinicaltrials.gov/ct2/show/NCT04402970,5,0,5,0,2,1,0,United States,dornase alfa
NCT04541979,6/4/2020,Interventional,Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19,Recruiting,Phase 2,Region Skane,https://clinicaltrials.gov/ct2/show/NCT04541979,5,0,5,0,0,0,0,Sweden,aerosolized dnase|sodium
NCT04445285,4/28/2020,Interventional,Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure,Recruiting,Phase 2,University of South Alabama,https://clinicaltrials.gov/ct2/show/NCT04445285,5,0,5,0,2,1,0,United States,pulmozyme/ recombinant human deoxyribonuclease (rh-dnase)|saline|pulmozyme|rh-dnase
NCT04402944,7/5/2020,Interventional,Pulmozyme to Improve COVID-19 ARDS Outcomes,Recruiting,Phase 2,Boston Children's Hospital,https://clinicaltrials.gov/ct2/show/NCT04402944,5,0,5,0,2,1,0,United States,pulmozyme|placebo
NCT04432987,5/25/2020,Interventional,Dornase Alpha for the Treatment of COVID-19,Recruiting,Phase 2,Acibadem University,https://clinicaltrials.gov/ct2/show/NCT04432987,5,0,5,0,0,0,0,Turkey,pulmozyme
NCT04353609,4/18/2020,Observational,"Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases",Recruiting,NA,"University Hospital, Lille",https://clinicaltrials.gov/ct2/show/NCT04353609,1,0,1,0,1,0,0,France,"NA"
NCT04343053,4/8/2020,Interventional,Pro-thrombotic Status in Patients With SARS-Cov-2 Infection,"Active, not recruiting",N/A,University Hospital of Ferrara,https://clinicaltrials.gov/ct2/show/NCT04343053,1,0,1,0,2,0,0,Italy,sars-cov-2 infection
NCT04395807,6/3/2020,Interventional,Helmet CPAP Versus HFNC in COVID-19,Recruiting,N/A,Lund University,https://clinicaltrials.gov/ct2/show/NCT04395807,1,0,1,0,1,0,0,Sweden,cpap|oxygen
NCT04405739,6/16/2020,Interventional,The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID),Recruiting,Phase 2,"Ridgeback Biotherapeutics, LP",https://clinicaltrials.gov/ct2/show/NCT04405739,2,0,2,0,14,1,0,United States,eidd-2801|placebo
NCT04405570,6/16/2020,Interventional,"A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19",Recruiting,Phase 2,"Ridgeback Biotherapeutics, LP",https://clinicaltrials.gov/ct2/show/NCT04405570,2,0,2,0,15,1,0,United States,eidd-2801|placebo
NCT04645563,3/11/2020,Observational,Using Whatsapp for the Consultation,Completed,NA,Kafkas University,https://clinicaltrials.gov/ct2/show/NCT04645563,1,0,1,0,0,0,0,Turkey,sending thorax ct video images via smartphone applications
NCT04558476,9/1/2020,Interventional,Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation,Recruiting,Phase 2,University of Liege,https://clinicaltrials.gov/ct2/show/NCT04558476,1,0,1,0,0,0,0,Belgium,convalescent plasma|standard care
NCT04304053,3/18/2020,Interventional,Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention,Completed,Phase 3,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",https://clinicaltrials.gov/ct2/show/NCT04304053,1,0,1,0,9,0,0,Spain,treatment/prophylaxis|standard care|treatment|prophylaxis
NCT04476667,6/15/2020,Interventional,"Online Delivery of Psychotherapy, Tailored to Patients' Suffering From Mental Health Problems Due to COVID-19",Recruiting,N/A,Queen's University,https://clinicaltrials.gov/ct2/show/NCT04476667,1,0,1,0,0,0,0,Canada,psychotherapy
NCT04510623,3/17/2020,Observational,Host Response Mediators in Coronavirus (COVID-19) Infection,Recruiting,NA,University of British Columbia,https://clinicaltrials.gov/ct2/show/NCT04510623,1,0,1,0,0,0,0,Canada,ace/arb|standard care|arb|ace inhibitor
NCT04502108,4/1/2020,Observational,Behavior During and After COVID-19 Crisis,Recruiting,NA,Bern University of Applied Sciences,https://clinicaltrials.gov/ct2/show/NCT04502108,1,0,1,0,1,0,0,Switzerland,covid-19
NCT04369378,8/19/2020,Interventional,Effectiveness of Using a Meditation App in Reducing Anxiety and Improving Well-being During the Covid-19 Pandemic,Recruiting,N/A,Lake Erie College of Osteopathic Medicine,https://clinicaltrials.gov/ct2/show/NCT04369378,1,0,1,0,2,1,0,United States,meditation app usage
NCT04362059,6/18/2020,Interventional,A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19,Recruiting,N/A,University Hospital Southampton NHS Foundation Trust,https://clinicaltrials.gov/ct2/show/NCT04362059,1,20,21,0,3,0,0,United Kingdom,covsurf drug delivery system|standard care
NCT04348929,4/16/2020,Interventional,Birth Experience During COVID-19 Confinement,Recruiting,N/A,"Central Hospital, Nancy, France",https://clinicaltrials.gov/ct2/show/NCT04348929,1,0,1,0,3,0,0,France,questionnaire
NCT04351906,5/3/2020,Interventional,Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome,Recruiting,N/A,University of Giessen,https://clinicaltrials.gov/ct2/show/NCT04351906,1,1,2,0,5,0,0,Germany,ecco2r
NCT04444674,6/24/2020,Interventional,COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection,"Active, not recruiting",Phase 1/Phase 2,University of Oxford,https://clinicaltrials.gov/ct2/show/NCT04444674,3,0,3,1,4,0,0,South Africa,chadox1|saline
NCT04315480,3/12/2020,Interventional,Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis,"Active, not recruiting",Phase 2,UniversitÃ  Politecnica delle Marche,https://clinicaltrials.gov/ct2/show/NCT04315480,1,0,1,0,2,0,0,Italy,tocilizumab
NCT04444531,3/20/2020,Observational,Ozone Therapy and Coronavirus Disease of 2019 (COVID-19) Pneumonia,Completed,NA,Institut d'InvestigaciÃ³ BiomÃ¨dica de Girona Dr. Josep Trueta,https://clinicaltrials.gov/ct2/show/NCT04444531,1,0,1,0,3,0,0,Spain,"NA"
NCT04369690,4/3/2020,Observational,"The Psychological, Social, and Economic Impacts of COVID-19",Recruiting,NA,University of Ottawa,https://clinicaltrials.gov/ct2/show/NCT04369690,1,0,1,0,0,0,0,Canada,"NA"
NCT04555005,3/10/2020,Interventional,Mindfulness-based Crisis Intervention for COVID-19 Frontline Healthcare Workers During COVID-19,Completed,N/A,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,https://clinicaltrials.gov/ct2/show/NCT04555005,1,0,1,0,0,0,0,Spain,mindfulness
NCT04425629,6/16/2020,Interventional,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19",Recruiting,Phase 2/Phase 3,Regeneron Pharmaceuticals,https://clinicaltrials.gov/ct2/show/NCT04425629,1,0,1,0,16,1,0,United States|Romania,regn10933/regn10987 combination therapy|placebo|regn10933|regn10987
NCT04372186,5/14/2020,Interventional,A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,"Active, not recruiting",Phase 3,"Genentech, Inc.",https://clinicaltrials.gov/ct2/show/NCT04372186,1,0,1,0,6,1,0,United States|Brazil|Kenya|Mexico|Peru|South Africa,placebo|tocilizumab
NCT04371419,5/13/2020,Interventional,COVID-19 Health Messaging to Underserved Communities,Completed,N/A,"National Bureau of Economic Research, Inc.",https://clinicaltrials.gov/ct2/show/NCT04371419,1,0,1,0,2,1,0,United States,messaging
NCT04492904,7/23/2020,Observational,Singapore COVID-19 Chemosensory Tracking (SCCT) Study,Recruiting,NA,"Clinical Nutrition Research Centre, Singapore",https://clinicaltrials.gov/ct2/show/NCT04492904,1,0,1,0,0,0,0,Singapore,questionnaire|home-use test
NCT04501978,8/4/2020,Interventional,ACTIV-3: Therapeutics for Inpatients With COVID-19,Recruiting,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),https://clinicaltrials.gov/ct2/show/NCT04501978,1,0,1,0,19,1,0,United States|Denmark|Singapore|Spain,ly3819253|placebo|remdesivir|vir-7831|brii-196/brii-198|brii-196|brii-198
NCT04358380,4/15/2020,Observational,Liver Injury in Patients With COVID-19,Enrolling by invitation,NA,"Austral University, Argentina",https://clinicaltrials.gov/ct2/show/NCT04358380,1,0,1,0,2,0,0,Argentina,liver
NCT04344041,4/15/2020,Interventional,COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial),Recruiting,Phase 3,"University Hospital, Angers",https://clinicaltrials.gov/ct2/show/NCT04344041,1,0,1,0,4,0,0,France,cholecalciferol
NCT04635241,6/1/2020,Interventional,Inhaled Heparin for Hospitalised COVID-19 Patients,Recruiting,Phase 2/Phase 3,Australian National University,https://clinicaltrials.gov/ct2/show/NCT04635241,2,0,2,0,1,0,0,Argentina|Egypt,heparin
NCT04470427,7/27/2020,Interventional,"A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19","Active, not recruiting",Phase 3,"ModernaTX, Inc.",https://clinicaltrials.gov/ct2/show/NCT04470427,1,0,1,1,13,1,0,United States,placebo|mrna-1273
NCT04540029,5/6/2020,Observational,Measuring Outcomes of Maternal COVID-19-related Prenatal Exposure,Recruiting,NA,"IRCCS National Neurological Institute ""C. Mondino"" Foundation",https://clinicaltrials.gov/ct2/show/NCT04540029,1,0,1,0,0,0,0,Italy,maternal stress
NCT04344327,4/10/2020,Observational,Early Risk Stratification of Patient Hospitalized for SARS-CoV2 Infection: Critical COVID-19 France CCF,Completed,NA,French Cardiology Society,https://clinicaltrials.gov/ct2/show/NCT04344327,1,0,1,0,1,0,0,France,"NA"
NCT04336410,4/3/2020,Interventional,"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers","Active, not recruiting",Phase 1,Inovio Pharmaceuticals,https://clinicaltrials.gov/ct2/show/NCT04336410,1,0,1,1,8,1,0,United States,ino-4800|cellectraâ® 2000
NCT04382235,3/26/2020,Observational,Non-invasive Ventilatory Support of Patients Affected by COVID-19,"Active, not recruiting",NA,University of Milano Bicocca,https://clinicaltrials.gov/ct2/show/NCT04382235,1,0,1,0,1,0,0,Italy,non-invasive ventilatory support
NCT04549376,7/1/2020,Interventional,Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo,Recruiting,Phase 2,"Pi Research Consultancy Center, Bangladesh",https://clinicaltrials.gov/ct2/show/NCT04549376,1,0,1,0,0,0,0,Bangladesh,povidone-iodine|placebo
NCT04414631,8/6/2020,Interventional,Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19,Recruiting,Phase 2,"University Hospital, Basel, Switzerland",https://clinicaltrials.gov/ct2/show/NCT04414631,1,0,1,0,4,0,0,Switzerland,conestat alfa
NCT04459286,10/9/2020,Interventional,The Nitazoxanide Plus Atazanavir for COVID-19 Study,Recruiting,Phase 2,Obafemi Awolowo University,https://clinicaltrials.gov/ct2/show/NCT04459286,1,0,1,0,2,0,0,Nigeria,nitazoxanide/atazanavir/ritonavir|standard care|nitazoxanide|atazanavir|ritonavir
NCT04463706,6/1/2020,Observational,COVID19 Severity Prediction and Health Services Research Evaluation,Recruiting,NA,Hospital Galdakao-Usansolo,https://clinicaltrials.gov/ct2/show/NCT04463706,1,0,1,0,1,0,0,Spain,predictors adverse evolution|predictors of health care provide
NCT04345536,3/15/2020,Observational [Patient Registry],Prospective Quality Register of Patients With Confirmed Covid-19 at Oslo University Hospital,Recruiting,NA,Oslo University Hospital,https://clinicaltrials.gov/ct2/show/NCT04345536,1,0,1,0,0,0,0,Norway,"NA"
NCT04479163,6/4/2020,Interventional,Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2,Completed,N/A,Fundacion Infant,https://clinicaltrials.gov/ct2/show/NCT04479163,1,0,1,0,3,0,0,Argentina,convalescent plasma|placebo
NCT04615429,9/15/2020,Interventional,Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19,Recruiting,Phase 2,Puerta de Hierro University Hospital,https://clinicaltrials.gov/ct2/show/NCT04615429,1,0,1,0,1,0,0,Spain,mesenchymal stem cells|placebo
NCT04422418,7/1/2020,Observational,Impact of Burnout on Cardiovascular and Immune Biomarkers in Healthcare Professionals - Covid-19 Pandemic in Abu Dhabi,Recruiting,NA,Khalifa University for Science and Technology,https://clinicaltrials.gov/ct2/show/NCT04422418,1,0,1,0,1,0,0,United Arab Emirates,"NA"
NCT04385121,4/16/2020,Observational,Psychological Impact of the Hospitalization of a Family Member in Intensive Care for Covid-19 Infection,Recruiting,NA,"University Hospital, Strasbourg, France",https://clinicaltrials.gov/ct2/show/NCT04385121,1,0,1,0,1,0,0,France,questionnaire
NCT04338009,3/31/2020,Interventional,Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019,Enrolling by invitation,N/A,University of Pennsylvania,https://clinicaltrials.gov/ct2/show/NCT04338009,1,0,1,0,1,1,0,United States,discontinuation of arb|continuation of arb|ace inhibitor
NCT04484493,8/8/2020,Interventional,Corticosteroid Nasal Spray in COVID-19 Anosmia,Completed,Phase 3,Benha University,https://clinicaltrials.gov/ct2/show/NCT04484493,1,0,1,0,5,0,0,Egypt,mometasone furoate nasal spray
NCT04438980,5/15/2020,Interventional,Glucocorticoids in COVID-19 (CORTIVID),Recruiting,Phase 3,Fundacion Miguel Servet,https://clinicaltrials.gov/ct2/show/NCT04438980,1,0,1,0,1,0,0,Spain,methylprednisolone|placebo
NCT04472728,6/16/2020,Interventional,Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients,Recruiting,Phase 2/Phase 3,Biophytis,https://clinicaltrials.gov/ct2/show/NCT04472728,1,0,1,0,5,1,0,United States|Belgium|Brazil|France|Puerto Rico,bio101|placebo
NCT04389645,4/7/2020,Observational,Interferon Gamma Induced Protein 10 (IP-10) in a Clinical Decision Support Protocol in COVID-19 Patients,Completed,NA,MeMed Diagnostics Ltd.,https://clinicaltrials.gov/ct2/show/NCT04389645,1,0,1,0,0,0,0,Israel,ip-10
NCT04458337,3/13/2020,Observational,SURgical Outcomes in COvid Patients - the SUROCO Multicenter Cohort Study (COVID-19),Recruiting,NA,Centre hospitalier de l'UniversitÃ© de MontrÃ©al (CHUM),https://clinicaltrials.gov/ct2/show/NCT04458337,1,0,1,0,3,0,0,Canada,"NA"
NCT04357938,4/15/2020,Observational,Risk Stratification With Chest CT to Rule-out Suspected SARS-CoV-2 Infections,"Active, not recruiting",NA,Jena University Hospital,https://clinicaltrials.gov/ct2/show/NCT04357938,1,0,1,0,1,0,0,Germany,ct-scan
NCT04330261,3/18/2020,Observational,Clinical Characteristics and Outcomes of Pediatric COVID-19,Recruiting,NA,University of Calgary,https://clinicaltrials.gov/ct2/show/NCT04330261,1,0,1,0,0,0,0,Canada,exposure
NCT04385771,9/1/2020,Interventional,Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Recruiting,N/A,University Hospital Freiburg,https://clinicaltrials.gov/ct2/show/NCT04385771,1,0,1,0,2,0,0,Germany,vv-ecmo / cytokine adsorption|vv-ecmo|cytokine adsorption
NCT04364893,4/9/2020,Interventional,Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19,Recruiting,N/A,D'Or Institute for Research and Education,https://clinicaltrials.gov/ct2/show/NCT04364893,1,0,1,0,2,0,0,Brazil,suspension/maintenance of angiotensin receptor blockers/angiotensin-converting enzyme inhibitors|suspension|maintenance|ace inhibitor
NCT04344145,4/16/2020,Observational,Exhaustion and Needs in Frontline COVID-19 Healthcare Workers: Cross-sectional Study in a Belgian Population,Completed,NA,UniversitÃ© Libre de Bruxelles,https://clinicaltrials.gov/ct2/show/NCT04344145,1,17,18,0,4,0,0,Belgium,"NA"
NCT04346602,2/1/2020,Observational,A Study on the Clinical and Psychological Characteristics of Patients With COVID-2019,Recruiting,NA,Jilin University,https://clinicaltrials.gov/ct2/show/NCT04346602,1,0,1,0,0,0,0,China,all treatment about covid-2019
NCT04345523,4/3/2020,Interventional,Convalescent Plasma Therapy vs. SOC for the Treatment of COVID19 in Hospitalized Patients,Recruiting,Phase 2,Puerta de Hierro University Hospital,https://clinicaltrials.gov/ct2/show/NCT04345523,1,0,1,0,1,0,0,Spain,blood/derivatives|standard care|blood|derivatives.
NCT04403685,5/8/2020,Interventional,Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,Terminated,Phase 3,BeneficÃªncia Portuguesa de SÃ£o Paulo,https://clinicaltrials.gov/ct2/show/NCT04403685,1,0,1,0,3,0,0,Brazil,tocilizumab
NCT04319731,3/20/2020,Interventional,A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure,Recruiting,Early Phase 1,University of Utah,https://clinicaltrials.gov/ct2/show/NCT04319731,1,0,1,0,1,1,0,United States,human amniotic fluid
NCT04282902,2/4/2020,Interventional,A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection,Recruiting,Phase 3,Tongji Hospital,https://clinicaltrials.gov/ct2/show/NCT04282902,0,4,4,0,0,0,0,China,pirfenidone
NCT04321369,3/9/2020,Observational,Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals,Completed,NA,UnitedHealth Group,https://clinicaltrials.gov/ct2/show/NCT04321369,0,2,2,0,1,1,0,United States,testing sensitivity for sars-cov-2 virus in symptomatic individuals
NCT04328480,4/17/2020,Interventional,The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.,Recruiting,Phase 3,Estudios ClÃ­nicos Latino AmÃ©rica,https://clinicaltrials.gov/ct2/show/NCT04328480,0,7,7,0,4,0,0,Argentina,colchicine|standard care
NCT04333550,4/30/2020,Interventional,Application of Desferal to Treat COVID-19,Recruiting,Phase 1/Phase 2,Kermanshah University of Medical Sciences,https://clinicaltrials.gov/ct2/show/NCT04333550,0,17,17,0,2,0,0,"Iran, Islamic Republic of",deferoxamine
NCT04333875,3/20/2020,Observational [Patient Registry],Morbidity and Mortality Due to Deferral of Aortic Valve Replacement in Patients With Severe Aortic Stenosis,"Active, not recruiting",NA,"University Hospital Inselspital, Berne",https://clinicaltrials.gov/ct2/show/NCT04333875,0,13,13,0,2,0,0,Switzerland,tavr/savr|tavr|savr
NCT04335097,4/22/2020,Interventional,Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation,Recruiting,N/A,Oslo University Hospital,https://clinicaltrials.gov/ct2/show/NCT04335097,0,2,2,0,3,0,0,Norway,biosensor
NCT04338568,4/16/2020,Interventional,Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study,Recruiting,N/A,Hasselt University,https://clinicaltrials.gov/ct2/show/NCT04338568,0,2,2,0,3,0,0,Belgium,lung ultrasound
NCT04340349,5/11/2020,Interventional,Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals,Enrolling by invitation,Early Phase 1,Instituto Nacional de Rehabilitacion,https://clinicaltrials.gov/ct2/show/NCT04340349,0,10,10,0,2,0,0,Mexico,hydroxychloroquine|bromhexine hydrochloride|hydroxychloroquine sulfate placebo|bromhexine 8 mg placebo
NCT04340921,5/14/2020,Observational,The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury,Recruiting,NA,Barts & The London NHS Trust,https://clinicaltrials.gov/ct2/show/NCT04340921,0,39,39,0,1,0,0,United Kingdom,exposure
NCT04342637,4/10/2020,Observational,COVID-19 Endoscopy Survey,Completed,NA,Al-Azhar University,https://clinicaltrials.gov/ct2/show/NCT04342637,0,9,9,0,3,1,0,"United States|Egypt|Iran, Islamic Republic of",practice details
NCT04343742,4/1/2020,Observational,Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19,Recruiting,NA,Genesis Foundation,https://clinicaltrials.gov/ct2/show/NCT04343742,0,1,1,0,1,0,0,Colombia,chlorine dioxide
NCT04343898,4/1/2020,Observational,Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19,"Active, not recruiting",NA,Brigham and Women's Hospital,https://clinicaltrials.gov/ct2/show/NCT04343898,0,10,10,0,8,1,0,United States,no intervention
NCT04344951,4/6/2020,Interventional,"Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial",Recruiting,Phase 2,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,https://clinicaltrials.gov/ct2/show/NCT04344951,0,9,9,0,1,0,0,Greece,chloroquine
NCT04346264,4/27/2020,Observational,CoVid-19 - Infection and Antibody Formation in the Viennese Population,Enrolling by invitation,NA,Ludwig Boltzmann Institute for Lung Health,https://clinicaltrials.gov/ct2/show/NCT04346264,0,1,1,0,1,0,0,Austria,no intervention planned due to the observational study design only a diagnostic testing
NCT04353583,4/21/2020,Observational [Patient Registry],Renal Outcome in Patients With COVID-19,Recruiting,NA,University of Giessen,https://clinicaltrials.gov/ct2/show/NCT04353583,0,1,1,0,7,0,0,Germany,"NA"
NCT04353674,4/28/2020,Interventional,Modulation of Hyperinflammation in COVID-19,Recruiting,N/A,Lawson Health Research Institute,https://clinicaltrials.gov/ct2/show/NCT04353674,0,36,36,0,5,0,0,Canada,control|sledd with a l-mod
NCT04356482,5/20/2020,Interventional,CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19,Recruiting,Phase 1/Phase 2,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,https://clinicaltrials.gov/ct2/show/NCT04356482,0,9,9,0,3,0,0,Mexico,convalescent plasma
NCT04359095,8/18/2020,Interventional,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Recruiting,Phase 2/Phase 3,Universidad Nacional de Colombia,https://clinicaltrials.gov/ct2/show/NCT04359095,0,41,41,0,1,0,0,Colombia,emtricitabine/tenofovir|colchicine pill|rosuvastatin|standard care|emtricitabine|tenofovir
NCT04360837,5/6/2020,Interventional,PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill Corona Virus Disease-19 (COVID-19) Patients,Recruiting,N/A,Szeged University,https://clinicaltrials.gov/ct2/show/NCT04360837,0,4,4,0,2,0,0,Hungary,alveolar
NCT04361942,5/1/2020,Interventional,Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV),Recruiting,Phase 2,Red de Terapia Celular,https://clinicaltrials.gov/ct2/show/NCT04361942,0,5,5,0,2,0,0,Spain,mesenchymal stem cells|placebo
NCT04366089,3/26/2020,Interventional,Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora,Recruiting,Phase 2,Azienda Policlinico Umberto I,https://clinicaltrials.gov/ct2/show/NCT04366089,0,4,4,0,0,0,0,Italy,oxygen-ozone|sivomixx|azithromycin|hydroxychloroquine|standard care
NCT04366232,8/19/2020,Interventional,Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation,Terminated,Phase 2,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,https://clinicaltrials.gov/ct2/show/NCT04366232,0,14,14,0,5,0,0,France,anakinra|anakinra/ruxolitinib|standard care|3)|ruxolitinib
NCT04367883,3/1/2020,Observational,"Influenza Vaccination, ACEI and ARB in the Evolution of SARS-Covid19 Infection",Recruiting,NA,Consorci Sanitari de Terrassa,https://clinicaltrials.gov/ct2/show/NCT04367883,0,1,1,0,2,0,0,Spain,ace inhibitor|arb
NCT04367896,3/24/2020,Observational,COVID-19 OUTBREAK AND SOLID ORGAN TRANSPLANTATION (SOT) : AN INTERNATIONAL WEB-BASED SURVEY,Completed,NA,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,https://clinicaltrials.gov/ct2/show/NCT04367896,0,4,4,0,0,0,0,Italy,questionnaire
NCT04368351,3/1/2020,Observational,Bacteriotherapy in the Treatment of COVID-19,"Active, not recruiting",NA,University of Roma La Sapienza,https://clinicaltrials.gov/ct2/show/NCT04368351,0,5,5,0,1,0,0,Italy,sivomixx|azithromycin|hydroxychloroquine
NCT04368897,5/1/2020,Observational,In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity,Recruiting,NA,"Applied Biology, Inc.",https://clinicaltrials.gov/ct2/show/NCT04368897,0,4,4,0,3,0,0,Spain,cag
NCT04369807,4/21/2020,Observational,Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection,Recruiting,NA,Perspectum,https://clinicaltrials.gov/ct2/show/NCT04369807,0,39,39,0,0,0,0,United Kingdom,mri
NCT04374123,4/20/2020,Observational,COVID-19 Serology Screening and Strict Protocol in the Endoscopy Unit,Completed,NA,Instituto Ecuatoriano de Enfermedades Digestivas,https://clinicaltrials.gov/ct2/show/NCT04374123,0,3,3,0,1,0,0,Ecuador,igm/igg rapid test|igg antibody test|igm antibodytest
NCT04374422,4/10/2020,Observational,COVID-19 Pandemic and Female Sexual Behavior,Completed,NA,Acibadem University,https://clinicaltrials.gov/ct2/show/NCT04374422,0,2,2,0,0,0,0,Turkey,fsfi survey
NCT04374786,5/15/2020,Interventional,Effects of Mobile App in House Staff Health and Well-being During COVID-19 Pandemic,Enrolling by invitation,N/A,University of Arizona,https://clinicaltrials.gov/ct2/show/NCT04374786,0,4,4,0,2,1,0,United States,meditation
NCT04378738,5/1/2020,Interventional,Social Media and Covid19 Pandemic,Enrolling by invitation,N/A,Acibadem University,https://clinicaltrials.gov/ct2/show/NCT04378738,0,1,1,0,0,0,0,Turkey,questionnaire
NCT04382768,5/1/2020,Interventional,Inhaled Ibuprofen to Treat COVID-19,Recruiting,N/A,QuÃ­mica Luar SRL,https://clinicaltrials.gov/ct2/show/NCT04382768,0,4,4,0,3,0,0,Argentina,ibuprofen
NCT04384380,4/1/2020,Interventional,Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19,Completed,N/A,Taoyuan General Hospital,https://clinicaltrials.gov/ct2/show/NCT04384380,0,19,19,0,1,0,0,Taiwan,hydroxychloroquine
NCT04385043,5/1/2020,Interventional,Hyperimmune Plasma in Patients With COVID-19 Severe Infection,Recruiting,Phase 2/Phase 3,University of Catanzaro,https://clinicaltrials.gov/ct2/show/NCT04385043,0,4,4,0,0,0,0,Italy,convalescent plasma|standard care
NCT04385901,5/19/2020,Interventional,Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth,Recruiting,N/A,University of Missouri-Columbia,https://clinicaltrials.gov/ct2/show/NCT04385901,0,2,2,0,2,1,0,United States,therapy intervention
NCT04391829,8/31/2020,Interventional,Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males,Recruiting,N/A,Universitair Ziekenhuis Brussel,https://clinicaltrials.gov/ct2/show/NCT04391829,0,1,1,0,1,0,0,Belgium,ejaculated semen sample
NCT04392141,4/1/2020,Interventional,Colchicine Plus Phenolic Monoterpenes to Treat COVID-19,Recruiting,Phase 1/Phase 2,Kermanshah University of Medical Sciences,https://clinicaltrials.gov/ct2/show/NCT04392141,0,6,6,0,2,0,0,"Iran, Islamic Republic of",standard care|colchicine/herbal phenolic monoterpene fractions|colchicine|herbal phenolic monoterpene
NCT04392323,5/13/2020,Interventional,Incidence of COVID-19 Test Conversion in Post-surgical Patients,Recruiting,N/A,Northwell Health,https://clinicaltrials.gov/ct2/show/NCT04392323,0,32,32,0,0,1,0,United States,pcr/serology|pcr|serology test
NCT04392713,4/15/2020,Interventional,Efficacy of Ivermectin in COVID-19,Recruiting,N/A,"Combined Military Hospital, Pakistan",https://clinicaltrials.gov/ct2/show/NCT04392713,0,2,2,0,0,0,0,Pakistan,ivermectin
NCT04393636,6/5/2020,Interventional,Digital Cardiac Counseling Trial: DCC Trial,Recruiting,N/A,Academisch Ziekenhuis Maastricht,https://clinicaltrials.gov/ct2/show/NCT04393636,0,14,14,0,1,0,0,Netherlands,digital cardiac counseling
NCT04393727,5/1/2020,Interventional,Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19,Terminated,Phase 2,"Azienda Ospedaliero, Universitaria Pisana",https://clinicaltrials.gov/ct2/show/NCT04393727,0,2,2,0,2,0,0,Italy,convalescent plasma
NCT04394182,4/21/2020,Interventional,Ultra Low Doses of Therapy With Radiation Applicated to COVID-19,Recruiting,N/A,Fundacion GenesisCare,https://clinicaltrials.gov/ct2/show/NCT04394182,0,10,10,0,0,0,0,Spain,radiotherapy|oxygen|lopinavir/ritonavir|hydroxychloroquine|azithromycin|piperacillin/tazobactam|heparin|corticosteroid|tocilizumab|lopinavir|ritonavir|piperacillin|tazobactam
NCT04402853,2/1/2020,Observational,SARS Cov-2 in Conjunctival Secretion in COVID-19 Patients,Completed,NA,UniversitÃ  degli Studi dell'Insubria,https://clinicaltrials.gov/ct2/show/NCT04402853,0,1,1,0,1,0,0,Italy,tears swab
NCT04407169,6/1/2020,Observational,Prevalence of Critical Forms of CoVid-19 in Patients With Chronic Respiratory Disease,Completed,NA,"Central Hospital, Nancy, France",https://clinicaltrials.gov/ct2/show/NCT04407169,0,21,21,0,1,0,0,France,no intervention
NCT04407468,5/1/2020,Observational,Awake Prone Positioning and Oxygen Therapy in Patients With COVID-19,Completed,NA,Hospital General San Juan del Rio,https://clinicaltrials.gov/ct2/show/NCT04407468,0,10,10,0,1,0,0,Mexico,prone positioning
NCT04407689,6/8/2020,Interventional,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort,Recruiting,Phase 2,Revimmune,https://clinicaltrials.gov/ct2/show/NCT04407689,0,19,19,0,2,0,0,France,placebo|interleukin
NCT04410328,10/21/2020,Interventional,Aggrenox To Treat Acute Covid-19,Recruiting,Phase 3,"Rutgers, The State University of New Jersey",https://clinicaltrials.gov/ct2/show/NCT04410328,0,6,6,0,4,1,0,United States,dipyridamole er 200mg/ aspirin 25mg orally/enterally/standard of care|standard care|dipyridamole er 200mg|aspirin 25mg orally|enterally
NCT04411446,8/11/2020,Interventional,Cholecalciferol to Improve the Outcomes of COVID-19 Patients,Recruiting,Phase 4,Vitamin D Study Group,https://clinicaltrials.gov/ct2/show/NCT04411446,0,1,1,0,3,0,0,Argentina,vitamin d|placebo
NCT04416256,2/1/2020,Observational,COVID-19 Pandemic and Worldwide Organ Procurement,Recruiting,NA,Paris Translational Research Center for Organ Transplantation,https://clinicaltrials.gov/ct2/show/NCT04416256,0,1,1,0,0,0,0,France,"NA"
NCT04416919,7/15/2020,Interventional,Assessment of N-95 Facemask for Use in COVID-19 Pandemic in Case of Shortage of Personal Protective Equipment,Recruiting,N/A,University of Oklahoma,https://clinicaltrials.gov/ct2/show/NCT04416919,0,3,3,0,1,1,0,United States,assembled mask
NCT04418518,6/24/2020,Interventional,A Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness,Recruiting,Phase 3,Weill Medical College of Cornell University,https://clinicaltrials.gov/ct2/show/NCT04418518,0,2,2,0,1,1,0,United States,convalescent plasma
NCT04418557,4/28/2020,Observational [Patient Registry],COVID-19 and Obstetric Transmission,Recruiting,NA,University Hospitals Cleveland Medical Center,https://clinicaltrials.gov/ct2/show/NCT04418557,0,2,2,0,1,1,0,United States,pcr/serology|pcr|serology test
NCT04422353,5/1/2020,Interventional,Video Dance Class and Unsupervised Physical Activity During Covid-19 Pandemic in People With Parkinson's Disease,Recruiting,N/A,Federal University of Rio Grande do Sul,https://clinicaltrials.gov/ct2/show/NCT04422353,0,1,1,0,1,0,0,Brazil,video dance classes|unsupervised physical activities
NCT04422535,5/29/2020,Observational,Effects on the Qt Interval of COVID-19 Coronavirus Infection,Recruiting,NA,Hospital General Universitario Gregorio MaraÃ±on,https://clinicaltrials.gov/ct2/show/NCT04422535,0,14,14,0,0,0,0,Spain,"NA"
NCT04424836,5/15/2020,Observational,HFNC Treatment in COVID-19 Pneumonia,Completed,NA,Sisli Hamidiye Etfal Training and Research Hospital,https://clinicaltrials.gov/ct2/show/NCT04424836,0,6,6,0,2,0,0,Turkey,high flow nasal cannula
NCT04424953,6/1/2020,Interventional,To Compare Videolaryngoscope Against Direct Laryngoscope for Intubation When Powered Air Purifying Respirator is Worn,"Active, not recruiting",N/A,Singapore General Hospital,https://clinicaltrials.gov/ct2/show/NCT04424953,0,28,28,0,2,0,0,Singapore,mcgrath videolaryngoscope|laryngoscope
NCT04427969,6/15/2020,Observational,Early Prone Position on Coronavirus Disease 2019 Pneumonia,Completed,NA,Sisli Hamidiye Etfal Training and Research Hospital,https://clinicaltrials.gov/ct2/show/NCT04427969,0,8,8,0,2,0,0,Turkey,prone positioning
NCT04430023,5/15/2020,Observational,Epidemiological and Demographic Data From 150 Patients Diagnosed With Coronavirus Disease 2019 Pneumonia,Completed,NA,Sisli Hamidiye Etfal Training and Research Hospital,https://clinicaltrials.gov/ct2/show/NCT04430023,0,7,7,0,1,0,0,Turkey,epidemiological/demographic characteristics|epidemiological|demographic characteristics
NCT04435080,3/15/2020,Observational,Physical Rehabilitation in ICU in ARDS Patients With COVID-19,Completed,NA,KoÃ§ University,https://clinicaltrials.gov/ct2/show/NCT04435080,0,11,11,0,0,0,0,Turkey,"NA"
NCT04437719,6/29/2020,Interventional,"Prospective Cohort Study to Describe the Clinical Characteristics of COVID-19, the Acquired Immune Response and the Biological and Clinical Parameters of Patients Followed in Oncology by the Saint-Joseph Hospital Group for a Period of 6 Months During the COVID-19 Pandemic",Recruiting,N/A,Groupe Hospitalier Paris Saint Joseph,https://clinicaltrials.gov/ct2/show/NCT04437719,0,4,4,0,2,0,0,France,obvio-19 app
NCT04437940,6/15/2020,Observational,Evaluation of Vaginal Fluid for Covid-19 Positivity in Women With Positive Nasofarengeal Covid-19 Test,Completed,NA,Acibadem University,https://clinicaltrials.gov/ct2/show/NCT04437940,0,1,1,0,1,0,0,Turkey,pcr
NCT04441814,7/23/2019,Observational,FOUND - Ancillary Study to Smile Protocol NCT03654105,Enrolling by invitation,NA,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",https://clinicaltrials.gov/ct2/show/NCT04441814,0,13,13,0,1,0,0,Italy,"NA"
NCT04442178,9/15/2020,Interventional,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ),Recruiting,Phase 2,Revimmune,https://clinicaltrials.gov/ct2/show/NCT04442178,0,21,21,0,1,1,0,United States,cyt107|placebo
NCT04443140,3/15/2020,Observational [Patient Registry],Preeclampsia-like Syndrome Induced by COVID-19: Is it a Real Public Health Issue in Pregnancy During the Pandemic?,Completed,NA,Zeynep Kamil Maternity and Pediatric Research and Training Hospital,https://clinicaltrials.gov/ct2/show/NCT04443140,0,2,2,0,2,0,0,Turkey,pcr
NCT04445961,5/1/2020,Observational,Respiratory Mechanics and Gas Exchange in Patients With COVID-19 and Hypoxemic Acute Respiratory Failure,Completed,NA,I.M. Sechenov First Moscow State Medical University,https://clinicaltrials.gov/ct2/show/NCT04445961,0,11,11,0,1,0,0,Russian Federation,respiratory mechanics measurement|gas exchange measurement
NCT04449731,3/20/2020,Observational,Changes in Dietary Behaviours During the COVID-19 Outbreak Confinement in the Adult Population (COVIDiet_Int),Recruiting,NA,Universidad de Granada,https://clinicaltrials.gov/ct2/show/NCT04449731,0,2,2,0,3,0,0,Spain,"NA"
NCT04453579,3/9/2020,Observational [Patient Registry],"Bariatric Surgery During Lockdown, Impact of COVID-19 on Physical and Mental Health",Completed,NA,University of Rome Tor Vergata,https://clinicaltrials.gov/ct2/show/NCT04453579,0,3,3,0,0,0,0,Italy,telehealth
NCT04454606,5/1/2020,Interventional,The New Silicone N99 Half-Piece Respirator,Completed,N/A,Bangkok Metropolitan Administration Medical College and Vajira Hospital,https://clinicaltrials.gov/ct2/show/NCT04454606,0,1,1,0,0,0,0,Thailand,fit test|filtration test
NCT04459819,3/1/2020,Observational,Respiratory Physiotherapy in Severe COVID-19 Patients,Recruiting,NA,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",https://clinicaltrials.gov/ct2/show/NCT04459819,0,15,15,0,1,0,0,Italy,respiratory physiotherapy
NCT04466670,7/8/2020,Interventional,Hemostasis in COVID-19: an Adaptive Clinical Trial,Recruiting,Phase 3,University of Sao Paulo General Hospital,https://clinicaltrials.gov/ct2/show/NCT04466670,0,62,62,0,0,0,0,Brazil,heparin|acetylsalicylic acid|enoxaparin
NCT04468035,6/1/2020,Observational,Early Cognitive Assessment and Evolutionary Monitoring of Patients With Severe ARDS on COVID-19 Pneumonia Requiring Mechanical Ventilation,Recruiting,NA,Groupe Hospitalier Paris Saint Joseph,https://clinicaltrials.gov/ct2/show/NCT04468035,0,4,4,0,2,0,0,France,"NA"
NCT04475471,6/11/2020,Observational,WORLD HEART FEDERATION (WHF) COVID-19 and Cardiovascular Disease Survey,Recruiting,NA,Public Health Foundation of India,https://clinicaltrials.gov/ct2/show/NCT04475471,0,22,22,0,1,0,0,"Argentina|Bosnia and Herzegovina|Ghana|India|Iran, Islamic Republic of|Sudan","NA"
NCT04476589,7/1/2020,Observational,Prognostication of Recovery in Early Disorders of Consciousness After COVID-19,Recruiting,NA,Massachusetts General Hospital,https://clinicaltrials.gov/ct2/show/NCT04476589,0,2,2,0,1,1,0,United States,functional mri
NCT04479202,2/8/2020,Interventional,The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19,Completed,Phase 4,Chinese Medical Association,https://clinicaltrials.gov/ct2/show/NCT04479202,0,12,12,0,0,0,0,China,berberine|montmorrillonite
NCT04480034,7/15/2020,Observational,Obesity Surgery During 2020 Italian Pandemic,Recruiting,NA,University of Roma La Sapienza,https://clinicaltrials.gov/ct2/show/NCT04480034,0,28,28,0,1,0,0,Italy,bariatric procedures
NCT04480593,6/2/2020,Interventional,The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.,Completed,Phase 2/Phase 3,D'Or Institute for Research and Education,https://clinicaltrials.gov/ct2/show/NCT04480593,0,12,12,0,1,0,0,Brazil,brazilian green propolis extract (epp-af)|standard care
NCT04482634,9/1/2020,Interventional,Tele-rehabilitation Versus Home Exercise Program in COVID-19,Recruiting,N/A,KoÃ§ University,https://clinicaltrials.gov/ct2/show/NCT04482634,0,11,11,0,1,0,0,Turkey,remote controlled exercise|home exercise
NCT04485169,4/1/2020,Interventional,Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm;,Completed,N/A,UNICEF,https://clinicaltrials.gov/ct2/show/NCT04485169,0,1,1,0,1,0,0,Pakistan,therapeutic plasma exchange (tpe)
NCT04485364,4/14/2020,Observational,Place of Circulating Biomarkers and Respiratory Eicosanoids in the Prognosis of Severe Forms of Covid-19 Pneumonia,"Active, not recruiting",NA,Groupe Hospitalier Paris Saint Joseph,https://clinicaltrials.gov/ct2/show/NCT04485364,0,4,4,0,0,0,0,France,"NA"
NCT04486001,12/15/2020,Interventional,Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19,Recruiting,Phase 1,"Sorrento Therapeutics, Inc.",https://clinicaltrials.gov/ct2/show/NCT04486001,0,1,1,0,3,1,0,United States,psc-04
NCT04486508,7/30/2020,Interventional,Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19,Recruiting,Phase 3,Rajaie Cardiovascular Medical and Research Center,https://clinicaltrials.gov/ct2/show/NCT04486508,0,1,1,0,5,0,0,"Iran, Islamic Republic of",intermediate dose enoxaparin/ unfractionated heparin|standard prophylactic dose enoxaparin/ unfractionated heparin|atorvastatin|placebo|enoxaparin|heparin|standard prophylactic dose enoxaparin
NCT04488484,7/1/2020,Interventional,Medical and Serological Follow-up of the Staff of the Paris Saint-Joseph Hospital Group Infected With Severe Acute Respiratory Syndrome Coronavirus 2.,"Active, not recruiting",N/A,Groupe Hospitalier Paris Saint Joseph,https://clinicaltrials.gov/ct2/show/NCT04488484,0,5,5,0,1,0,0,France,serology test follow-up
NCT04494724,7/13/2020,Interventional,Clazakizumab vs. Placebo - COVID-19 Infection,Recruiting,Phase 2,The Methodist Hospital System,https://clinicaltrials.gov/ct2/show/NCT04494724,0,20,20,0,0,1,0,United States,clazakizumab|placebo
NCT04497311,6/15/2020,Observational,Tomographic Findings in COVID-19 and Influenza,Recruiting,NA,Universidad de Guanajuato,https://clinicaltrials.gov/ct2/show/NCT04497311,0,31,31,0,1,0,0,Mexico,thoraxic computed tomography
NCT04501965,6/1/2020,Interventional,Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Azythromycin in Asymptomatic Covid-19 Patients,Enrolling by invitation,Phase 2,Institute for Research and Development of Medicinal and Food Plants of Guinea,https://clinicaltrials.gov/ct2/show/NCT04501965,0,20,20,0,1,0,0,Guinea,4plants/azythromycin|hydroxychloroquine / azithromycin|quinquina-stevia/azythromycin|4plants|azithromycin|hydroxychloroquine|quinquina-stevia
NCT04502342,6/1/2020,Interventional,"Add on to Azythromycine, Phytomedicine and/or Antimalarial Drug vs Hydroxychloroquine in Uncomplicated COVID-19 Patients",Enrolling by invitation,Phase 2,Institute for Research and Development of Medicinal and Food Plants of Guinea,https://clinicaltrials.gov/ct2/show/NCT04502342,0,1,1,0,1,0,0,Guinea,hydroxychloroquine / azithromycin|cospherunate/azythromycine|cospherunate/phytomedicine/azythromycien|hydroxychloroquine|azithromycin|cospherunate|phytomedicine
NCT04503434,5/15/2020,Observational [Patient Registry],Patients' Experiences in a Medicalized Hotel for COVID-19 Acute Care Support,Completed,NA,Hospital Clinic of Barcelona,https://clinicaltrials.gov/ct2/show/NCT04503434,0,4,4,0,0,0,0,Spain,"NA"
NCT04508920,5/15/2019,Observational [Patient Registry],A Survey to Assess Effects of Covid-19 on Cardiovascular Patients,Recruiting,NA,"Centro en Insuficiencia Cardiaca, Mexico",https://clinicaltrials.gov/ct2/show/NCT04508920,0,1,1,0,0,0,0,Mexico,"survey|symptomatology, treatment. daily activities"
NCT04511429,6/30/2020,Observational [Patient Registry],COVID-19 in Immunosuppressed Children,Recruiting,NA,D'Or Institute for Research and Education,https://clinicaltrials.gov/ct2/show/NCT04511429,0,11,11,0,0,0,0,Brazil,"NA"
NCT04513964,11/1/2020,Observational,Impact of COVID-19 on the Benefit of Cardiac Rehabilitation,Recruiting,NA,Groupe Hospitalier Paris Saint Joseph,https://clinicaltrials.gov/ct2/show/NCT04513964,0,37,37,0,2,0,0,France,"NA"
NCT04514705,8/11/2020,Interventional,Characteristics in Post Covid-19 Patients,Recruiting,N/A,Universidade Metodista de Piracicaba,https://clinicaltrials.gov/ct2/show/NCT04514705,0,6,6,0,0,0,0,Brazil,exercise
NCT04515108,3/10/2020,Observational,Perinatal Outcomes and Hematologic Parameters in COVID-19 Pregnancies,Completed,NA,Ankara City Hospital Bilkent,https://clinicaltrials.gov/ct2/show/NCT04515108,0,4,4,0,0,0,0,Turkey,clinical assessment
NCT04516811,9/21/2020,Interventional,Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19,Recruiting,Phase 3,South African National Blood Service,https://clinicaltrials.gov/ct2/show/NCT04516811,0,1,1,0,2,0,0,South Africa,convalescent plasma/standard care|standard care/placebo|convalescent plasma|standard care|placebo
NCT04517162,8/19/2020,Interventional,Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients,Recruiting,Phase 1,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,https://clinicaltrials.gov/ct2/show/NCT04517162,0,50,50,0,2,0,0,Mexico,collagen-polyvinylpyrrolidone
NCT04517422,8/19/2020,Interventional,Efficacy of L. Plantarum and P. Acidilactici in Adults With SARS-CoV-2 and COVID-19,Recruiting,N/A,"AB Biotics, SA",https://clinicaltrials.gov/ct2/show/NCT04517422,0,7,7,0,3,0,0,Mexico,placebo|probiotics
NCT04522492,8/11/2020,Interventional,Impact of COVID-19 on Mental Health of Patients With Skin Picking,Enrolling by invitation,N/A,Hospital de Clinicas de Porto Alegre,https://clinicaltrials.gov/ct2/show/NCT04522492,0,2,2,0,1,0,0,Brazil,internet-based cognitive behavioral therapy|quality of life promotion
NCT04526405,7/14/2020,Observational,Frequency of COVID-19 Antibodies in Patients With Hereditary Hematological Diseases,Completed,NA,University of Milano Bicocca,https://clinicaltrials.gov/ct2/show/NCT04526405,0,4,4,0,1,0,0,Italy,sars-cov-2 s1/s2 igg|sars-cov-2 s1|igg test
NCT04530617,10/5/2020,Interventional,Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients,Recruiting,Phase 2,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,https://clinicaltrials.gov/ct2/show/NCT04530617,0,63,63,0,3,0,0,Mexico,camostat mesilate|artemisia annua leaf
NCT04535869,12/30/2020,Interventional,Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19),Recruiting,Phase 3,Mansoura University,https://clinicaltrials.gov/ct2/show/NCT04535869,0,2,2,0,2,0,0,Egypt,sofosbuvir 400 mg/daclatasvir 200mg|sofosbuvir 400 mg|daclatasvir 200mg
NCT04542512,10/1/2020,Observational [Patient Registry],Risk Factors for Necrotic Cholecystitis During COVID-19 Pandemic.,Recruiting,NA,Poissy-Saint Germain Hospital,https://clinicaltrials.gov/ct2/show/NCT04542512,0,6,6,0,2,0,0,France,"NA"
NCT04558996,3/1/2020,Observational [Patient Registry],Spanish Registry of Pregnant Women With COVID-19,Recruiting,NA,Puerta de Hierro University Hospital,https://clinicaltrials.gov/ct2/show/NCT04558996,0,1,1,0,0,0,0,Spain,"NA"
NCT04567927,3/3/2020,Observational,Prevalence and Risk Factors for Venous Thromboembolic Events in Critically Ill Patients With COVID-19,Completed,NA,"Ente Ospedaliero Cantonale, Bellinzona",https://clinicaltrials.gov/ct2/show/NCT04567927,0,32,32,0,0,0,0,Switzerland,ultrasonography
NCT04567979,6/11/2020,Observational,Prospective Determination of COVID-19 Infection Rate in a Chemotherapy Unit in Mexico.,"Active, not recruiting",NA,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,https://clinicaltrials.gov/ct2/show/NCT04567979,0,16,16,0,0,0,0,Mexico,"NA"
NCT04568356,4/24/2020,Interventional,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,Completed,N/A,"E25Bio, Inc.",https://clinicaltrials.gov/ct2/show/NCT04568356,0,19,19,0,1,1,0,United States,direct antigen tests for covid-19
NCT04570254,8/19/2020,Interventional,Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19,"Active, not recruiting",N/A,Unidad Temporal COVID-19 en Centro Citibanamex,https://clinicaltrials.gov/ct2/show/NCT04570254,0,13,13,0,1,0,0,Mexico,vitamin c|vitamin e|melatonin|n-acetyl cysteine|pentoxifylline
NCT04577105,4/1/2020,Observational,Risk Factors and Computed Tomography Findings in COVID-19.,Completed,NA,Instituto Nacional de Cardiologia Ignacio Chavez,https://clinicaltrials.gov/ct2/show/NCT04577105,0,19,19,0,1,0,0,Mexico,simple chest tomography
NCT04581928,10/10/2020,Observational,Patients Reactions Towards Their Diagnosis as Having COVID-19,Recruiting,NA,ClinAmygate,https://clinicaltrials.gov/ct2/show/NCT04581928,0,1,1,0,1,0,0,Egypt,"NA"
NCT04594356,11/19/2020,Observational,"Assessment of Netosis During COVID-19, Under Treatment With Anakinra, an Interleukin-1 Receptor Antagonist",Recruiting,NA,Groupe Hospitalier Paris Saint Joseph,https://clinicaltrials.gov/ct2/show/NCT04594356,0,17,17,0,1,0,0,France,"NA"
NCT04597034,10/2/2020,Interventional,Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) vs (Standard AN-69) in COVID-19,Recruiting,N/A,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,https://clinicaltrials.gov/ct2/show/NCT04597034,0,5,5,0,0,0,0,Mexico,an69-oxiris|an69-standard
NCT04604249,10/26/2020,Observational,Prevalence of COVID-19 in High Altitude : Insights From the Highest City of the World,Recruiting,NA,Centre d'Expertise sur l'Altitude EXALT,https://clinicaltrials.gov/ct2/show/NCT04604249,0,6,6,0,0,0,0,Peru,"sars-cov-2 rapid diagnostic test (covid-prestoâ® igm/igg, aaz, boulogne-billancourt, france)|sars-cov-2 rapid diagnostic test (covid-prestoâ® igm|igg, aaz, boulogne-billancourt, france)"
NCT04608097,10/28/2020,Interventional,Understanding Reactions to Emotional Material in the Media During COVID-19,Recruiting,N/A,Uppsala University,https://clinicaltrials.gov/ct2/show/NCT04608097,0,1,1,0,1,0,0,Sweden,simple cognitive task intervention|placebo
NCT04610541,10/12/2020,Interventional,REMdesivir-HU Clinical Study and Severe Covid-19 Patients,"Active, not recruiting",Phase 3,University of Pecs,https://clinicaltrials.gov/ct2/show/NCT04610541,0,6,6,0,1,0,0,Hungary,remdesivir-hu
NCT04610554,5/14/2020,Observational,Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide Early After Mild-to-severe COVID-19,Completed,NA,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",https://clinicaltrials.gov/ct2/show/NCT04610554,0,1,1,0,0,0,0,Italy,"NA"
NCT04610567,10/27/2020,Interventional,Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19),Recruiting,Phase 1/Phase 2,University of Sao Paulo General Hospital,https://clinicaltrials.gov/ct2/show/NCT04610567,0,10,10,0,2,0,0,Brazil,methotrexate-lde phase 1|methotrexate-lde phase 2|placebo-lde phase 2
NCT04611269,3/20/2020,Observational [Patient Registry],Clinical Characteristics and Outcomes of Patients With COVID-19 on Mechanical Ventilation in Argentina,Completed,NA,Argentinian Intensive Care Society,https://clinicaltrials.gov/ct2/show/NCT04611269,0,28,28,0,3,0,0,Argentina,"NA"
NCT04615416,5/1/2020,Interventional,Emotion Regulation Training Via Telehealth During the COVID-19 Pandemic,Recruiting,N/A,"Teachers College, Columbia University",https://clinicaltrials.gov/ct2/show/NCT04615416,0,2,2,0,0,1,0,United States,emotion regulation training via telehealth
NCT04616950,12/1/2020,Observational,Impact of the COVID-19 Epidemic on the Hospital Journey of Patients With Cancer of the Digestive System,Recruiting,NA,Groupe Hospitalier Paris Saint Joseph,https://clinicaltrials.gov/ct2/show/NCT04616950,0,5,5,0,2,0,0,France,"NA"
NCT04623697,11/1/2020,Observational [Patient Registry],Covid-19 Infection and New Onset Type 1 Diabetes,Recruiting,NA,Hospital of South West Jutland,https://clinicaltrials.gov/ct2/show/NCT04623697,0,10,10,0,0,0,0,Denmark,"NA"
NCT04624503,10/1/2020,Observational,Prognostic and Clinical Impact of Cardiovascular Involvement in Patients With COVID-19,Recruiting,NA,"Humanitas Hospital, Italy",https://clinicaltrials.gov/ct2/show/NCT04624503,0,1,1,0,0,0,0,Italy,"NA"
NCT04625985,7/14/2020,Interventional,"Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.",Recruiting,Phase 2,Laboratorios Silanes S.A. de C.V.,https://clinicaltrials.gov/ct2/show/NCT04625985,0,5,5,0,0,0,0,Mexico,metformin glycinate|placebo
NCT04627467,3/28/2020,Interventional,Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID),"Active, not recruiting",Phase 2,Fundacion Clinica Valle del Lili,https://clinicaltrials.gov/ct2/show/NCT04627467,0,39,39,0,0,0,0,Colombia,chloroquine
NCT04629183,11/1/2020,Observational,Risk Stratification of COVID-19 Patients Discharged From the Emergency Department,Recruiting,NA,Azienda Ospedaliera CittÃ  della Salute e della Scienza di Torino,https://clinicaltrials.gov/ct2/show/NCT04629183,0,3,3,0,1,0,0,Italy,integrated clinical evaluation
NCT04631861,1/1/2014,Observational,Physical Activity and the Risk of COVID-19 Infection and Mortality,Completed,NA,Wonju Severance Christian Hospital,https://clinicaltrials.gov/ct2/show/NCT04631861,0,5,5,0,0,0,0,NA,"NA"
NCT04632615,5/22/2020,Observational,Sleep Behaviour in Athletes During Home Confinement Due to the Covid-19 Outbreak,Recruiting,NA,Istituto Ortopedico Galeazzi,https://clinicaltrials.gov/ct2/show/NCT04632615,0,8,8,0,0,0,0,Italy,"NA"
NCT04638842,12/24/2020,Interventional,Online Multi-component Psychological Intervention for Prevention of Grief Disorder Due to COVID-19,Recruiting,N/A,Universidad Internacional de Valencia,https://clinicaltrials.gov/ct2/show/NCT04638842,0,8,8,0,2,0,0,Mexico,online intervention grief covid-19
NCT04642326,6/26/2020,Interventional,Study Investigating the Effects of UVC Beam and Laser Beam Therapy According to Standard Therapy in Patients With Covid-19 Diagnosis,"Active, not recruiting",N/A,RD Global AraÅŸtirma GeliÅŸtirme SaÄŸlik IlaÃ§ InÅŸaat Yatirimlari A.Åž.,https://clinicaltrials.gov/ct2/show/NCT04642326,0,7,7,0,0,0,0,Turkey,test group: experimental - uvc therapy applied
NCT04643522,1/7/2020,Observational,Semen Parameters and COVID-19 in Infertile Men,Completed,NA,Ankara City Hospital Bilkent,https://clinicaltrials.gov/ct2/show/NCT04643522,0,5,5,0,1,0,0,Turkey,clinical assessment
NCT04647695,11/20/2020,Interventional,IFN-beta 1b and Remdesivir for COVID19,Recruiting,Phase 2,The University of Hong Kong,https://clinicaltrials.gov/ct2/show/NCT04647695,0,2,2,0,2,0,0,Hong Kong,interferon|remdesivir
NCT04659200,9/1/2020,Observational,Thyroid Function Tests and Status of Thyroid Autoantibodies in Covid-19 Patients,Recruiting,NA,Bezmialem Vakif University,https://clinicaltrials.gov/ct2/show/NCT04659200,0,1,1,0,1,0,0,Turkey,venous blood was collected for biochemistry testing.
NCT04661631,5/8/2020,Observational [Patient Registry],Surgery and Lung Ultrasound in COVID-19 Infection,Recruiting,NA,Fundacion Clinica Valle del Lili,https://clinicaltrials.gov/ct2/show/NCT04661631,0,56,56,0,1,0,0,Colombia,lung ultrasound
NCT04662437,9/10/2020,Observational,The Status of Parathyroid Hormone Secretion in Covid-19 Patients,Completed,NA,Bezmialem Vakif University,https://clinicaltrials.gov/ct2/show/NCT04662437,0,3,3,0,0,0,0,Turkey,venous blood was collected for biochemistry testing
NCT04668404,8/24/2020,Observational [Patient Registry],Study of Coagulation Profile and Role of Heparin Like Effect in Patients With COVID-19,Recruiting,NA,Postgraduate Institute of Medical Education and Research,https://clinicaltrials.gov/ct2/show/NCT04668404,0,18,18,0,0,0,0,India,sonoclot
NCT04673214,12/16/2020,Interventional,Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment,Recruiting,Phase 3,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",https://clinicaltrials.gov/ct2/show/NCT04673214,0,10,10,0,2,0,0,Mexico,azithromycin / ivermectin / ribaroxaban / paracetamol|azithromycin / ribaroxaban / paracetamol|azithromycin|ivermectin|ribaroxaban|paracetamol
NCT04679168,6/1/2020,Observational [Patient Registry],Study on Kidney Disease and EnviromenTal Chemical,Recruiting,NA,Seoul National University Hospital,https://clinicaltrials.gov/ct2/show/NCT04679168,0,3,3,0,1,0,0,"Korea, Republic of","NA"
NCT04685512,11/18/2020,Interventional,Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged Home,Recruiting,Phase 2/Phase 3,"University Hospital, Caen",https://clinicaltrials.gov/ct2/show/NCT04685512,0,5,5,0,0,0,0,France,tenofovir disoproxil/emtricitabine|tenofovir disoproxil|emtricitabine
NCT04689672,12/16/2020,Observational,Predictivity of Hemogasanalysis and Lung UltraSound in Determining COVID-19 Severity,Recruiting,NA,IRCCS San Raffaele,https://clinicaltrials.gov/ct2/show/NCT04689672,0,6,6,0,0,0,0,Italy,lung ultrasound
NCT04691921,1/4/2021,Observational,Current Pharmacological Practices in Severe COVID-19,Recruiting,NA,NMC Specialty Hospital,https://clinicaltrials.gov/ct2/show/NCT04691921,0,7,7,0,3,0,0,India,current clinical practices of participating physicians
NCT04700163,1/15/2021,Interventional,RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers,Recruiting,Phase 1,Rockefeller University,https://clinicaltrials.gov/ct2/show/NCT04700163,0,1,1,0,1,1,0,United States,c144-ls/c-135-ls|c144-ls|c-135-ls
NCT04700254,12/28/2020,Observational,"Anxiety, Depression and Eating Attitudes of Diabetes Mellitus Patients During COVID-19 Lockdown in Greece",Completed,NA,"Chania General Hospital ""St. George""",https://clinicaltrials.gov/ct2/show/NCT04700254,0,5,5,0,3,0,0,Greece,dass questionnaire|eat-26 questionnaire
NCT04705753,4/1/2020,Interventional,"Assessment of the Clinical Effectiveness of a Herbal Extract (Cretan IAMA) in Patients With Viral Respiratory Infections, Including COVID-19, in Primary Healthcare Settings, and Co-assessment of Its Prophylactic Effect in People Cohabiting With These Patients",Completed,Phase 2/Phase 3,University of Crete,https://clinicaltrials.gov/ct2/show/NCT04705753,0,4,4,0,0,0,0,Greece,cretan iama
NCT04706325,1/1/2021,Observational,COVID-19 RELATED KIDNEY DAMAGE,Recruiting,NA,Kocaeli Derince Education and Research Hospital,https://clinicaltrials.gov/ct2/show/NCT04706325,0,3,3,0,0,0,0,Turkey,acute kidney injury
NCT04712292,9/8/2020,Observational,Effects of COVID-19 Pandemic on the Diagnosis and Outcomes of Colorectal Cancer (COVID-CRC),Recruiting,NA,University of Bologna,https://clinicaltrials.gov/ct2/show/NCT04712292,0,7,7,0,0,0,0,Italy,surgical procedure for cancer
